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Abstract

Delirium, a prevalent disorder in older adults, is an acute brain dysfunction characterized by disturbances in
attention, awareness and cognition not explained by a pre-existing neurocognitive disorder. The ICU
Liberation Executing the ABCDEF Bundle Daily (iLEAD) is a nurse-driven intervention aimed at reducing
the consequences of delirium in the intensive care unit (ICU). It was posited that when nurses routinely assess
non-modifiable risk factors and manage modifiable risk factors for delirium, including those related to pain
and pain management, patient outcomes will improve. This dissertation research: 1) systematically reviewed
the use of the pharmacotherapy dexmedetomidine to treat or prevent delirium (Chapter 2); 2) compared
patient outcomes in older adults with delirium in the surgical ICU (SICU) before and after implementation of
the iLEAD intervention (Chapter 3); and 3) assessed the relationship among pain, its treatment with opioids,
and the onset of delirium in the post-implementation cohort (Chapter 4). The pre- and post-iLEAD
intervention cohorts consisted of 93 patients who developed delirium while admitted to the SICU at the
Hospital of the University of Pennsylvania. The analysis evaluated the effects of implementing the iLEAD
protocol on the number of days of delirium, SICU and hospital length of stay, 30-day readmission and 30-day
mortality. In addition, this research examined the role of pain, pain management with opioids, and delirium
onset. Results from this study have meaningfully contributed to better informed care of older adult patients
with delirium in critical care environments.
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ABSTRACT
EVALUATING THE EFFECTS OF A NURSE-LED INTERVENTION
FOR DELIRIUM AND PAIN MANAGEMENT AMONG OLDER ADULTS IN THE
SURGICAL INTENSIVE CARE UNIT
Kara J. Pavone
Peggy Compton
Rosemary C. Polomano
Delirium, a prevalent disorder in older adults, is an acute brain dysfunction characterized
by disturbances in attention, awareness and cognition not explained by a pre-existing
neurocognitive disorder. The ICU Liberation Executing the ABCDEF Bundle Daily
(iLEAD) is a nurse-driven intervention aimed at reducing the consequences of delirium in
the intensive care unit (ICU). It was posited that when nurses routinely assess nonmodifiable risk factors and manage modifiable risk factors for delirium, including those
related to pain and pain management, patient outcomes will improve. This dissertation
research: 1) systematically reviewed the use of the pharmacotherapy dexmedetomidine
to treat or prevent delirium (Chapter 2); 2) compared patient outcomes in older adults
with delirium in the surgical ICU (SICU) before and after implementation of the iLEAD
intervention (Chapter 3); and 3) assessed the relationship among pain, its treatment
with opioids, and the onset of delirium in the post-implementation cohort (Chapter 4).
The pre- and post-iLEAD intervention cohorts consisted of 93 patients who developed
delirium while admitted to the SICU at the Hospital of the University of Pennsylvania.
The analysis evaluated the effects of implementing the iLEAD protocol on the number of
days of delirium, SICU and hospital length of stay, 30-day readmission and 30-day
mortality. In addition, this research examined the role of pain, pain management with
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opioids, and delirium onset. Results from this study have meaningfully contributed to
better informed care of older adult patients with delirium in critical care environments.
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Chapter 1
Introduction
Delirium is the most common complication affecting hospitalized older adults (age  65
years) admitted to the intensive care unit (ICU),1 totaling more than 2.6 million older
adults in the United States (U.S.) each year.2 Delirium is defined as an acute change in
cognition and attention not explained by a pre-existing condition or established or
evolving dementia.3 Spending the majority of their time at the bedside, nurses are at the
forefront of delivering care in the ICU. As the U.S. population continues to age, nurses
will be continually challenged with identifying, managing and treating delirium. Not
surprisingly, the economic burden of delirium is significant with total costs attributable to
the condition estimated at $164 billion (2011 U.S. dollars) per year. 4 Moreover, delirium
contributes to distress in both patients and caregivers, and is associated with long-term
cognitive deficits,5-10 a greater likelihood for needing residential care posthospitalization,5-10 and increased mortality.11-13 Delirium can be a life-threatening
condition, yet with early identification and management it may be preventable. 1
Nurses are uniquely prepared to drive solutions to address this clinically significant
problem by recognizing risk factors and initiating evidence-based nursing interventions.
To date, no single cause or mechanism for delirium has been identified. Postulated
mechanisms contributing to delirium include; inflammation, neurotransmitter disruptions,
physiological stressors, metabolic derangements and genetic factors. 2 Commonly
recognized risk factors for delirium in surgical intensive care unit (SICU) patients are
pain, and its treatment with opioids.2,14,15 Pain is defined as an unpleasant physical
and/or emotional experience related to potential or actual tissue damage, 16 and the
physiological stress associated with unrelieved pain is believed to contribute to
delirium.15,17 The cognitive effects of the primary class of medications used to manage
1

acute pain, opioids, have also been implicated in the development of delirium.14,15,17 A
systematic review of 14 studies found that that risk of developing delirium was 2.5 times
greater in patients receiving opioids.18 Studying the relative roles of pain and pain
management on the onset of delirium is vital to improve patient outcomes.
The 2013 Society for Critical Care Medicine Clinical Practice Guidelines for
Management of Pain, Agitation, and Delirium (PAD)19 recommends routine monitoring of
pain, sedation and delirium for all patients in the ICU. To encourage dissemination of
these guidelines, the Society for Critical Care Medicine created ICU Liberation which
utilizes the so-called “ABCDEF bundle” to help guide care (Figure 1.1). The individual
and collective elements of the ABCDEF bundle aim to ameliorate delirium, improve pain
management, and reduce levels of deep sedation, leading to improved outcomes for
adult patients in the ICU. Utilizing the principles of health systems science, which
encompass improving quality, outcomes, and costs of health care delivery for patients
and populations within systems of medical care,20 in 2018 the Hospital of the University
of Pennsylvania (HUP) implemented the ICU Liberation Executing the ABCDEF Bundle
Daily (iLEAD) protocol (see APPENDIX A). The goal of iLEAD is to empower nurses to
improve delirium-related outcomes by employing evidence-based nursing interventions.
The overall objectives of this research were to: 1) determine if implementation of
the iLEAD intervention resulted in fewer days of delirium, decreased length of stay in the
SICU and hospital, and improved 30-day patient outcomes among patients in the SICU;
and 2) evaluate the relationships among pain severity, opioid analgesic administration
and the onset of delirium. The central hypothesis of this dissertation research is that
implementation of the nurse-led iLEAD intervention will reduce the consequences of
delirium in hospitalized older adults.

2

Specifically, a retrospective pre- and post-implementation cohort study was
performed to assess the impact of the iLEAD intervention on delirium and patient
outcomes in critically ill patients in the SICU aged 65 years and older. A convenience
sample of patients were examined from March to August 2017 for the preimplementation cohort and from March to August 2018 for the post-implementation
cohort; the intervention was implemented in January 2018. Primary outcome measures
were days of delirium, SICU length of stay, hospital length of stay, 30-day readmission
rates and 30-day mortality. Secondly, in the post-implementation cohort, a crosssectional study examined the relationships among pain severity, pain management with
opioids, and the onset of delirium. The specific aims were to:
Specific Aim 1: Complete an integrative review of publications in peer-reviewed
journals evaluating the use of a novel pharmacotherapy, dexmedetomidine, for the
prevention and/or treatment of delirium. This review served as the foundation for the
dissertation research aims and hypotheses by providing an increased understanding of
the most current treatment strategies, delirium research methods, and the issues
associated with identifying and managing delirium (Chapter 2).
Specific Aim 2: Compare outcomes (days of delirium, SICU length of stay, hospital
length of stay, 30-day readmission and 30-day mortality rates) between older adults in
the pre- and post-iLEAD intervention cohorts (Chapter 3).
Hypothesis 1: Patients’ delirium, pain and healthcare utilization outcomes (SICU
length of stay, hospital length of stay, 30-day readmission and 30-day mortality rates)
will improve when nurses routinely assess and manage modifiable risk factors for
delirium (i.e., implementing the iLEAD intervention).
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Specific Aim 3: Evaluate the relationships among pain severity, opioid analgesic
administration, and the onset of delirium in older adults in the SICU in the postintervention cohort (Chapter 4).
Hypothesis 1: Pain severity scores will be positively correlated with the onset of
delirium.
Hypothesis 2: Exposure to opioid analgesics will be positively correlated with the
onset of delirium.
With respect to outcomes, this work provides findings to 1) determine if early
identification and prevention strategies associated with the iLEAD intervention result in
fewer days of delirium and better delirium-related clinical outcomes; and 2) examine the
relative roles of pain and opioid pain management on the onset of delirium.
Background
Delirium is an acute change in awareness and attention developed over a short course,
with likely disruption to cognitive processing, that is not better described by a preexisting, established or evolving condition.3 Patients with delirium can experience altered
perceptions of reality that are intense, and induce feelings of panic, uncertainty or
distress.21 They may have trouble communicating their distress and feel misunderstood
by family members and health care providers.
The clinical presentation of delirium is classified into three subtypes; hyperactive,
hypoactive, or mixed.10 With hyperactive delirium, patients may by hyperalert and exhibit
restlessness and agitation. In contrast, those with hypoactive delirium generally present
as lethargic or sedated and respond slowly to questions or show little purposeful
movement. Patients with mixed delirium demonstrate the features of both hyper- and
hypoactive delirium. Notably, older adults are more likely to express hypoactive delirium,

4

and too often, these patients go unnoticed or are mistakenly identified as having
dementia or depression.1
A 2003 study by Poole and Mott reported that when caring for patients with
hyperactive delirium, nurses’ often felt frustrated and irritated, admitting that these
patients were difficult to work with and took up too much of their time, citing ‘‘nothing
else gets done’’ (p. 309).22 With respect to hypoactive delirium, recent literature found
that nurses failed to detect delirium in up to three out of four cases.23,24 Further, even
when identified, interventions aimed at its management were not consistently
implemented. Investigators showed that some clinicians view delirium as an inevitable
part of a hospital stay for older adult patients, while others see it as a transient condition
from which patients can recover without long-term consequences and clinical
implications.4 Failure to recognize and manage delirium, stemming from its lack of
pathognomonic features, can be a life-threatening issue for older adult patients with
delirium.25 Taken together, these concerns represent a critical gap in clinical
practice that results in nurses and other healthcare professionals poorly
identifying patients with delirium and initiating new approaches to minimize its
consequences.
Delirium in Older Adults in the Intensive Care Unit
Delirium is believed to occur in approximately 50% of all older hospitalized adults 1 and
70-87% of older adults admitted to the ICU following surgery.10 Following a systemic
challenge, such as surgery, older adults are increasingly vulnerable to developing
delirium secondary to hypothesized inflammatory processes, neurotransmitter
disruptions, physiological stressors, and metabolic derangements.2,5,26-28 In addition,
aging itself has been described as a risk factor for developing delirium.5,26-28 A
substantial proportion of patients who survive delirium are likely to experience long-term
5

cognitive impairment similar to mild Alzheimer’s disease5-10,29 for up to one year postdischarge.19 A recent study placed the odds of requiring of institutional care following
hospitalization at rates 2.4 times higher in patients who suffer from delirium than those
who did not.30
In addition to being a serious health threat, delirium is a costly condition. 5,10,24,29,31 An
investigation of one-year health care costs associated with delirium in older adult
patients showed that patients with delirium are 2.5 times more costly than patients
without delirium.32 Supplementary costs per hospitalization attributable to delirium range
from $16,303 to $64,421 per patient.4 While causal relationships have not been
established specifically in SICU patients, there is evidence linking increased length of
stay and higher mortality rates in older adult patients with delirium in general ICU
settings.11
Effects of Delirium on Patient and Healthcare Outcomes
The impact of delirium on patients and health care systems is substantial. A report by
the American Association of Retired Persons identifies delirium as one of six leading
causes of injuries associated with hospitalization in patients over 65 years of age. 33 Key
patient and health care outcomes associated with delirium include days of delirium,
SICU and hospital length of stay, 30-day readmissions and 30-day mortality.
Days of Delirium and Length of Stay. Delirium is associated with longer ICU and overall
hospital lengths of stays.34 Of patients who develop delirium in the medical ICU, the
typical length of stay ranges from four to five days, with an average of two to three days
of delirium.11,34,35 Ely and colleagues showed that the number of days spent in a delirious
state predicted length of stay.34 Among a cohort of non-ventilated critically ill patients,
delirium was associated with a one-day longer ICU stay and a two-day longer overall
hospital stay.36 A recent systematic review estimated that the average length of stay in
6

patients with delirium in the ICU was 1 day and 9 hours longer than patients without
delirium.37 Compared to patients who never develop delirium, patients undergoing a
delirious episode may spend a median of 10 days longer in the hospital. At any given
time over the course of their hospitalization, patients with delirium had an adjusted risk of
staying in the hospital that was two times higher than those who never developed
delirium.11 Reducing the number of days with delirium, and ICU and hospital stays would
lessen the health and economic burdens to patients and healthcare systems.
30-day Readmissions. Medicare and Medicaid reimbursements are reduced to hospitals
with excessive 30-day readmissions,38 and some of the delirium-related costs cited
above are attributed to readmissions of patients with delirium. In addition to costs,
hospital readmissions are associated with unfavorable patient outcomes. 39 Hospitals are
now connecting with entities across the healthcare industry to implement best practices
in reducing readmission rates, including the prevention, early diagnosis and treatment of
delirium.39 In a study of older adult patients undergoing cardiac surgery, of those
readmitted within 30 days for any reason, 80% had delirium during their initial inpatient
stay.40 However, little evidence is available describing the impact of days of delirium on
hospital readmissions, a key driver of healthcare costs.4,32,39,40
30-day Mortality. Delirium has also been identified as an independent marker for
increased mortality in older medical inpatients during the 12 months following
hospitalization.41 ICU delirium is associated with a 2- to 4-fold increased risk of overall
mortality1 with the duration of ICU delirium linked with one-year all-cause mortality.35
Investigators demonstrated that 50% of patients who were delirious during their ICU stay
died within one year post-hospitalization.35 A hallmark study by Ely and colleagues
documented that in patients receiving mechanical ventilation, ICU delirium was an
independent predictor of mortality, such that during a six-month follow-up, 34% of the
7

patients in the delirium group died versus 15% of the patients without delirium. 11 This
corresponded with a greater than three times higher risk of dying within 6-months of
hospital discharge.11
Nurse-Led Interventions for Delirium
Devising innovative strategies to assess, prevent and manage delirium is well within the
scope of nursing practice. Nurses are at the forefront of care and many evidence-based
delirium interventions do not require a physician’s order.42,43 Nurse-led models of care
have been used in a variety of settings, including promoting optimal aging of older
adults,44 managing diabetes45 and cardiovascular risk,45 improving medication
adherence,46 expanding palliative care,47 and reducing pre-surgical anxiety.48 This study
capitalized on the clinical acumen of nurses who routinely care for older adults in the
SICU by expanding previous nurse-driven protocols49,50 and routine clinical assessments
to include interventions to help prevent and/or manage delirium.
Current strategies aimed at reducing the severity of delirium involve the recognition
of non-modifiable risk factors and amelioration of modifiable risk factors (Figure 1.2).
Many of these risk factors are routinely evaluated as part of a critical care nursing
assessment. Non-modifiable risk factors for delirium outlined in the iLEAD protocol
include: advancing age ( 65 years); history of dementia or cognitive impairment; prior
history of delirium, stroke, neurological disease, falls or gait disorder; visual or hearing
impairments and two or more chronic health conditions.51 Modifiable risk factors include:
pain; sensory impairment (hearing or vision); immobilization (catheters or restraints);
medications that have the potential for psychoactive effects on the central nervous
system (sedatives, hypnotics, opioids, anticholinergic drugs, corticosteroids,
polypharmacy); surgery; environment (for example, admission to an ICU); emotional
distress; and sustained sleep deprivation.51
8

Reliance on nurse-led interventions is especially critical in view of the lack of
effective pharmacologic interventions to treat delirium. To date, no single
pharmacological intervention has been demonstrated to be effective in its treatment.5 A
number of pharmacological strategies to both prevent and treat delirium have been, and
continue to be actively tested, including antipsychotic medications, 52
acetylcholinesterase inhibitors,53 melatonin,54 benzodiazepines,55,56 intravenous
acetaminophen57 and gabapentin.53 In addition, numerous studies suggest that use of
the alpha-2 agonist, dexmedetomidine, may reduce the incidence or duration of delirium
(Chapter 2) by addressing its underlying cause, ameliorating pain or preserving sleep
architecture.5,26,28,51,58,59 However, thus far, no single pharmacologic strategy has
amassed enough evidence to support its role in delirium prevention or treatment. Hence,
it is critical that nurses have a firm understanding of the risk factors for delirium and the
non-pharmacological interventions available to help reduce the incidence and duration of
delirium. Understanding these risk factors and treatment strategies will aid nurses in
providing optimal care and advocating for patients’ needs.
The development of the ABCDEF bundle (Awake and pain free; spontaneous
Breathing trials: Consideration of Analgesia and Sedation; Delirium; Exercise; Family
engagement) has been well-described in the literature and published in numerous peerreviewed high-impact journals.60-63 While many studies have reviewed the effectiveness
of the individual elements of the ABCDEF bundle, few have evaluated the effect of
implementing the bundle as a whole.64-68 In January 2019, the first large scale evaluation
of the ABCDEF bundle was published. This multicenter, prospective cohort study led by
the Society of Critical Care Medicine ICU Liberation Collaborative included over 15,000
adult patients (18+ years of age) from 68 ICUs (including mixed medical/surgical,
medical, surgical/trauma, neurological, cardiac/surgical and surgical). The primary
9

objective of this analysis was to evaluate the relationship between ABCDEF bundle
performance on patient and healthcare systems outcomes.68 Complete performance of
the ABCDEF bundle (i.e., a patient day in which every eligible element of the bundle was
performed) was associated with a lower likelihood of next-day mechanical ventilation,
delirium, ICU readmission and 7-day mortality. The impressive results of this large-scale
trial show that implementation of the ABCDEF bundle can improve patient and health
system-level outcomes.
Similarly, the iLEAD intervention evaluated in this study is based on the
implementation of the ABCDEF bundle, with its goal being to enable nurses to monitor
sedation, manage pain more effectively, and ameliorate delirium utilizing independent
nursing interventions (APPENDIX A). The iLEAD intervention includes three key
standardized assessments; the Richmond Agitation-Sedation Scale (RASS) to measure
level of sedation, the Confusion Assessment Method for the Intensive Care Unit (CAMICU) to screen for delirium, and the numeric rating scale to measure pain severity.
Based on their assessment findings, nurses are guided to manage delirium, analgesia
and sedation while also utilizing the interventions of early mobility and family
engagement interventions.
Specifically, upon admission to the SICU, a patient’s level of sedation was assessed
with the RASS tool, which is the first step in completing the CAM-ICU to screen for the
presence of delirium. RASS evaluates a patient’s level of sedation on a -5 (unarousable)
to +4 (combative) scale, with 0 corresponding to calm and alert. Patients with a RASS of
-4 or -5 are unable to be assess by the CAM-ICU. Patients with a positive CAM-ICU
score are evaluated for new infections, or cardiac or neurological events that may
explain the change in their mental status. Inpatient and home medications are also
reviewed to evaluate high-risk medications, such as opioids and benzodiazepines.
10

Nurses are then encouraged to employ at least two independent non-pharmacological
interventions from a menu of interventions (Table 1.1) to help manage the delirium.
Additional collaboration with the interdisciplinary team is then required to determine the
potential cause of delirium and appropriate treatment approaches. Delirium is continually
reassessed using the CAM-ICU every 12 hours to monitor responses to the
interventions.
A limited number of studies have examined the effectiveness of these independent
nursing interventions, although the use of such supportive measures has nevertheless
become standard practice on the basis on clinical experience and lack of adverse
effects.10 A systematic review of 39 trials in non-ICU patients concluded that
multicomponent interventions (interventions included an educational component,
individualized care, reorientation, and early mobilization) concurrently targeting several
risk factors are effective in prevention of delirium (reduction in incident of delirium by
approximately one-third).69 The review cites moderately strong evidence to support the
use of these interventions in delirium prevention, but provide less robust evidence to
support decreasing severity or duration of delirium. 69 Reducing known risk factors and
precipitants of delirium may decrease the factors contributing to, and possibly
prolonging, an episode of delirium.70 Ultimately, more research is needed to understand
the benefits of individual nursing interventions on reducing the number of days of a
delirious episode and other delirium-related patient outcomes.
Pain
Pain is a potent and common stressor present in approximately 80% of critically ill
patients admitted in the SICU.71 Related to the surgical incision, and/or tissue
manipulation and removal during surgical procedure, moderate to severe pain is present
in up to three out of four postsurgical patients.72 In addition, the majority of patients
11

regard some degree of pain following surgery as ‘‘necessary’’ (p. 1093). 72 Due to its
subjective nature, pain can only be reported by the individual who is experiencing it. 73
Verbal rating scales, numerical rating scales and visual analogue scales provide simple,
effective, and minimally invasive measures of pain intensity; however, many patients
admitted to the ICU are unable to report their pain because of mechanical ventilation,
neuromuscular blockade, or deep sedation.74 When pain is not routinely assessed and
managed, patients may be inappropriately be given sedative medications rather than
analgesic medications.75 Payen and colleagues76 found that when routinely assessed for
pain, mechanically ventilated patients were more likely to receive analgesic medications
(non-opioids or opioids) and less likely to receive sedatives (in particular, deliriogenic
benzodiazepines) than patients who never had a pain assessment. 76
Older adults may be stoic or reticent about reporting pain for fear of complaining. 77 A
review by Schofield estimates that 50% to 60% of patients aged over 75 years suffer
pain or discomfort, yet are consistently less likely than younger patients to receive
appropriate pain management.77 In addition, both the peripheral and central nociceptive
nervous systems are affected by the aging process, including reductions in the
concentration of serotonin receptors and GABA synthesis, which are important
modulators of pain, resulting in slowing of endogenous inhibitory pain process and
increased sensitivity to pain in older adults.78 Finally, older adults are more likely to have
age-related changes in pharmacokinetics and pharmacodynamics related to analgesic
medication administration. Taken together, these changes in pain processing,
physiologic pain response and medication metabolism in older adults have important
implications in the management of their pain.
In critical care patients, suboptimal pain management has been associated with an
array of negative consequences, including increased cost of care, decreased quality of
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life, prolonged opioid use during and after hospitalization, and increased morbidity. 77,79-81
Uncontrolled pain is a stressor and can have harmful effects on several different body
systems including, cardiovascular, respiratory, musculoskeletal and, most notably,
cognitive function.17 Furthermore, unrelieved moderate to severe pain may lead to
persistent or chronic pain.79 The prevalence of persistent pain following major surgeries
remains between 10% and 30%.82 More aggressive analgesic measures are needed to
reduce the incidence and intensity of acute pain, and to prevent the evolution from acute
to chronic pain.79 In addition to chronic post-surgical pain, the consequences of
insufficient pain management also include sleep deprivation, fatigue, anxiety, and
delirium.82
Delirium and Pain
In the literature, untreated pain is frequently identified as a precipitating factor for the
development of delirium.19,80,81 In fact, in the iLEAD intervention, pain is identified as a
primary modifiable risk factor for delirium. However, there is surprisingly limited evidence
to support a causal relationship between pain and the development of delirium. Because
the relationship between pain and delirium has not been well-elucidated, there is no
evidence-based strategy to both pharmacologically manage pain and prevent delirium in
critically ill patients. Few studies have examined the SICU population and how the
presence of pain contributes to the occurrence of delirium,81 and conflicting data exist
regarding this relationship. Vaurio and colleagues in their investigation with older adults
scheduled for non-cardiac surgery concluded that pain was independently associated
with the development of delirium.81 In that any patient reports of pain are typically and
aggressively addressed with opioid administration in the inpatient setting, newer
evidence has not sufficiently drawn definitive conclusions about the relationship of pain
and delirium.
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Delirium and Opioid Analgesia
To date, pain management in the ICU has relied almost exclusively on opioid
administration.14,15 The mu-opioid receptors are involved in the regulation of sensory and
affective components of the pain experience. The most common opioids analgesics
used include; morphine, oxycodone, hydromorphone, hydrocodone, and fentanyl. For
acute pain, opioids are generally administered by intravenous and oral routes. Literature
suggests that pain management with opioids may be a precipitating factor for the
development of delirium.15 The method or mode of administration (oral, patientcontrolled analgesia, neuraxial, intravenous) of opioid administration appears to play a
more important role in the development of delirium than absolute dose, likely due to
onset of action.15 For example, the use of oral opioid analgesic as the primary means of
pain control is less likely to induce delirium compared to intravenous patient-controlled
analgesia.81 As previously noted, when prescribing pain management for older adults, it
is important to consider age-related changes in pharmacokinetics and
pharmacodynamics of opioid medications. Due to slowed drug metabolism, older adults
are more susceptible to the central nervous system depressant effects of these
medications.
Opioid use has been implicated in development of delirium in patients admitted to the
ICU83 and across various hospital settings.18 These medications have psychoactive and
depressant effects on cortical function, including cognitive performance, which may
contribute to the decline in cognitive function hallmark of delirium. 14,84 Opioids inhibit
calcium channel opening by binding to regulatory G-protein-coupled mu-opioid
receptors, and thereby block presynaptic terminal depolarization in cholinergic
pathways.85 This deficit in cholinergic activity is thought to contribute to delirium. 14 In a
study of 216 patients in a medical/surgical ICU, 40 patients developed delirium (19%),
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and use of opioid analgesics (morphine and epidural) was strongly correlated to the
development of delirium.83 A systematic review of 9 studies reported opioid use in both
medical, surgical and medical/surgical ICU settings, and concluded that opioids are a
risk factor for the development of delirium.18 However, these studies have limited
generalizability and were noted to be of low to moderate quality evidence. 18,83 Therefore,
the role of opioid analgesics in the development and duration of delirium requires
additional clarification.
Summary
Delirium is a significant and costly problem for older adults in the ICU. It is commonly
under-recognized and undertreated, and the consequences are not only evident in
length of SICU and hospital stay, but in the more worrisome outcomes of 30-day
readmissions and mortality. Empirical evidence for independent nurse-led interventions
to mitigate the development and duration of delirium is accumulating, and this evaluation
of the iLEAD intervention at HUP contributes to this body of knowledge. Interestingly,
both pain and opioid administration are identified as independent risk factors for the
development of delirium,15 suggesting that by attempting to ameliorate one risk factor
(pain), nurses may in fact be contributing to another (delirium). Examination of the
relative roles of pain and opioid administration on the onset of delirium experienced by
this population provides the foundation for evidence-based guidelines on pain
management approaches which minimize negative outcomes related to delirium.
Significance
The dissertation research is significant in two principal ways. First, this work focuses on
a uniquely nurse-led intervention. While iLEAD is described as an interdisciplinary
intervention, nurses are the key stakeholders driving this intervention forward. Their
clinical expertise and front-line responsibilities make nurses uniquely qualified to
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champion this effort and facilitate the prevention and management of delirium with the
interdisciplinary care team. Although nurse-led interventions have been demonstrated to
improve patient outcomes in multiple health problems (diabetes,45 cardiovascular
disease,45 medication adherence,46 palliative care,47 pre-surgical anxiety44), this is one of
the first evaluations to determine the impact of iLEAD bundled independent nursing
interventions to treat the significant and costly problem of ICU delirium.
Second, pain is commonly cited as a primary risk factor for the development of
delirium.86 However, close examination of the literature reveals that there is little
empirical evidence to support this oft-cited causal relationship. Further, the role of
pain management with opioids in the development of delirium requires explication. If, in
fact, untreated pain results in delirium, analgesia should improve delirium outcomes,
however the depressant cognitive effects of the analgesics most commonly used to treat
pain, opioids, may worsen delirium. This raises the question as to whether opioids
administered to counter pain-induced delirium contribute to its development. This study
is among the few to characterize the relative roles of pain and opioid administration on
the onset of delirium.
In summary, the overall contribution of this study is to describe the effectiveness of
the nurse-led iLEAD intervention to reduce the burden of delirium and its associated
adverse outcomes and to examine two modifiable risk factors associated with delirium
(i.e. pain, opioid administration). The variables examined in this study are described in
APPENDIX B. This dissertation research: 1) evaluates a nurse-led identification,
treatment and management strategy for delirium; 2) expands knowledge of deliriumrelated patient outcomes (days of delirium, length of stay, readmissions, mortality); and
3) facilitates continued investigation into the link between pain, opioid pain management
and the onset of delirium. Overall, this dissertation research has important implications in
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moving forward nurse-driven approaches to the clinical care of aging adults in critical
care environments at risk for experiencing delirium.
Chapter Aims and Rationale
The major goals of this dissertation research were to: 1) conduct an integrative review of
the literature to examine the use of dexmedetomidine to prevent and/or treat delirium
(Chapter 2); 2) determine if identification and prevention strategies associated with the
nurse-led iLEAD intervention result in fewer days of delirium and better delirium-related
clinical outcomes (Chapter 3); and 3) explicate the relative roles of pain and opioid pain
management on the onset of delirium (Chapter 4).
Chapter 2
Aim: To date, no single pharmacological intervention has been shown to be effective in
treating or preventing delirium. Studies suggest the novel alpha-2 agonist,
dexmedetomidine, may reduce or prevent delirium due to its unique actions on sleep
preservation and pain control. An integrative review of the literature to determine if use
of dexmedetomidine was associated with a lower incidence and/or duration of delirium
as compared to other non-dexmedetomidine pharmacologic strategies was conducted.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines directed this integrative review. A table of evidence reviews 16 high-quality
studies using dexmedetomidine for the prevention or treatment of delirium in three
patient populations: mechanically ventilated, those undergoing cardiac surgery and
those undergoing non-cardiac surgery. This work informed the aims addressed in the
data-based papers to follow, and presented a unique integrative review evaluating the
effects of dexmedetomidine for the prevention or treatment of delirium. This work has
been published in Heart & Lung: The Journal of Acute and Critical Care (2018 impact
factor 1.73).
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Rationale: The results of this review found that postoperative administration of
dexmedetomidine may reduce delirium in patients, particularly following cardiac surgery.
Further research is needed to determine the benefits of dexmedetomidine in patients on
mechanical ventilation and optimal timing and duration of administration. The themes
identified in this review informed the basis for this dissertation research and future lines
of inquiry. Specifically, the limitations of pharmacotherapy in treating delirium became
evident, and sorely missing from the studies reviewed was any discussion of the use or
effect of nurse-led interventions on reported outcomes. Further, the suggestion that
dexmedetomidine efficacy could be attributed to its analgesic effects, and therefore
opioid-sparing approaches, provided the foundation for research questions about the
relationships between pain, opioid pain management and delirium.
Chapter 3
Aim: Although protocolized nurse-led interventions have been evaluated for several
health conditions or diseases, the success of these in the management of SICU delirium
in older adult patients has not been empirically examined. Outcomes in older adult
patients in the SICU before and after the implementation of the iLEAD intervention, a
nurse-driven delirium assessment, treatment and management protocol, were
compared. Chapter 3 has been formatted for possible publication in The Joint
Commission Journal on Quality and Patient Safety (2018 acceptance rate 26.4%)
describing delirium outcomes before and after implementation of iLEAD in the SICU at
HUP.
Rationale: By 2060, it is estimated that older adults will comprise nearly 25% of the
population. Consequently, nurses in acute care settings will be challenged to care for
higher numbers of older adults experiencing delirium in future decades. Literature that
specifically addresses the effectiveness of delirium management interventions for older
18

adults admitted to the SICU is limited, and primarily focuses on comparing various
pharmacologic approaches. This data-based paper compares the number of days of
delirium and patient-centered delirium outcomes following implementation of the nurseled iLEAD intervention. This paper highlights the contributions of nurses in integrating
iLEAD into routine clinical care and explicates the impact of independent nurse-initiated
interventions on patient outcomes.
Chapter 4
Aim: Literature suggests that pain and opioid administration may each independently be
precipitating factors in the development of delirium. However, there is diverse and limited
evidence to support these relationships, particularly among older adults in the SICU. As
such, the relative roles of pain, opioid analgesic administration and the onset of delirium
were examined. The findings for this cross-sectional analysis are reported in Chapter 4
and formatted for publication in the American Journal of Critical Care (2018 impact factor
2.055) exploring the relative roles of acute pain and opioid administration on the onset of
delirium experienced by patients in the SICU at HUP.
Rationale: Limited evidence suggests that pain and use of opioids for pain
management are precipitating factors in the development of delirium. However, empirical
evidence to support the association between pain and delirium is sparse. In addition,
literature that specifically addresses the effects of pain and pain management on
delirium for older adults admitted specifically to the SICU is limited. This cross-sectional
analysis evaluated the relationships among pain, its management with opioids, and the
onset of delirium. This data-based paper is among the first to specifically evaluate the
relationships among the onset of delirium, pain and pain management following
implementation of the iLEAD intervention.
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Figures and Tables

Figure 1.1 ABCDEF Bundle

Figure 1.2 Conceptual Model of the iLEAD Intervention, Delirium and its
Consequences
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Table 1.1 Independent Non-Pharmacologic Nursing Interventions for Management
of Delirium
Manage pain (repositioning, massage, etc.)
Use communications tools
Ensure adequate nutrition, assist with
feeding
Constantly provide reorientation
Expose to sunlight
Provide physical activity
Encourage family engagement
Have eye glasses or hearing aids available
at the bedside

Provide music therapy
Adjust room temperature
Manage bowel and bladder
Provide cognitively simulating activities
Manage thirst sensation
Manage stimuli from tubes, lines and drains
Avoid physical restraints
Provide sleep hygiene with 2-4-hour blocks of
minimal interruptions and noise minimization
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Chapter 2
Evaluating the use of dexmedetomidine for the reduction of delirium:
An integrative review 1
Abstract
Delirium, an acute change in cognition and attention not secondary to a pre-existing
condition or dementia, affects nearly 40,000 hospitalized older adults in the United
States every day. Delirium is associated with increased healthcare costs of $16,303 to
$64,421 per patient. To date, no single pharmacological intervention is effective in
preventing or treating delirium in critically ill patients. Evidence suggests the alpha-2
agonist, dexmedetomidine, may reduce or prevent delirium. An integrative review
examined whether dexmedetomidine was associated with a lower incidence of delirium
compared to other analgesic and sedation strategies. PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) guided this review and 16
publications met quality criteria for inclusion. These studies support that postoperative
administration of dexmedetomidine may reduce delirium in patients, particularly following
cardiac surgery. Further research is needed to determine the benefits of
dexmedetomidine in patients on mechanical ventilation and optimal timing and duration
of administration.

This chapter is the author’s original work. A final version of this manuscript is published as Pavone, K. J., Cacchione, P.
Z., Polomano, R. C., Winner, L. & Compton, P. Evaluating the use of dexmedetomidine for the reduction of delirium: An
integrative review. Heart Lung 47, 591-601, doi:10.1016/j.hrtlng.2018.08.007 (2018). © 2018 Elsevier Inc. No
modifications are permitted without the permission of the copyright holder.
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Introduction
Delirium, a common problem for hospitalized older adults particularly after surgery or
with acute illness, is defined as an acute change in cognition and attention not described
by a pre-existing condition, established or evolving dementia. 1 Delirium contributes to
distress in patients, caregivers and families, and more seriously is associated with
increased mortality,2-4 long-term cognitive deficits, and a greater likelihood for requiring
post-hospitalization residential care.5-10 Older adult patients (ages  65) are more
vulnerable to developing delirium as a result of surgery and acute illness than younger
patients, and aging itself is a risk factor for developing delirium. By 2060, it is estimated
that the number of older adults in the United States will rise to 98.2 million, nearly 25% of
the population. Consequently, healthcare providers in acute care settings will be
expected to care for higher numbers of older adults with delirium in future decades.
To date, no single pharmacological intervention has been shown to be effective in
treating delirium.5 Multiple variables contribute to the development of delirium, including
underlying health conditions, but the pathophysiology of delirium remains poorly
understood. Current interventions for the prevention of delirium involve the recognition
and amelioration of modifiable risk factors. These risk factors include pain, immobility,
sleep disturbances, and exposure to medications that have the potential for
psychoactive effects on the central nervous system such as opioids and
benzodiazepines.11 A number of pharmacological strategies to both prevent and treat
delirium have been, and continue to be, highly tested including, antipsychotic
medications,12 acetylcholinesterase inhibitors,13 melatonin,14 benzodiazepines,15,16
corticosteroids, statins and gabapentin.13 Thus far, no single strategy has amassed
enough evidence to support its role in delirium prevention or treatment.
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Studies purport that dexmedetomidine (Precedex©) may reduce or prevent delirium. 5,1724

Dexmedetomidine, approved by the FDA in 1999 for short-term sedation (not to

exceed 24 hours), is the most specific alpha-2 receptor agonist currently used in clinical
care.25 Dexmedetomidine, like clonidine, exerts its anti-nociceptive effects in two ways.
Primarily, it acts at alpha-2 receptors in the descending inhibitory nociceptive pathway in
the spinal cord.26,27 Dexmedetomidine helps down-regulate nociceptive information
transmission by disinhibiting inhibitory interneurons, which in turn block early nociceptive
information transmission into the spinal cord by dorsal root ganglion neurons. 26
Dexmedetomidine also exerts a key anti-nociceptive effect by decreasing arousal.
Traditionally, dexmedetomidine is administered as an anesthetic adjunct in nonintubated patients prior to and/or during surgical and other procedures. Additionally, it is
indicated for sedation of intubated and mechanically ventilated patients in critical care
settings. Patients who are sedated with dexmedetomidine are arousable and responsive
in a manner that is similar to that seen in people who are sleeping. 28,29 The
neurophysiological and behavioral characteristics of the sedative state induced by
dexmedetomidine closely resemble non-rapid eye movement sleep.28,30,31
It is hypothesized that dexmedetomidine may reduce delirium by addressing its
underlying cause or ameliorating pain.5,17-21 Maldonado and colleagues5 attribute an
intrinsic “delirium-saving” property of all alpha-2 adrenoceptor agonists, which typically
have minimal effects on cognitive impairment. They postulate that dexmedetomidine
may lessen the occurrence and severity of delirium because it decreases the need for
gamma-Aminobutyric acid (GABA)ergic agents, benzodiazepines and opioids typically
required for sedation and analgesia.11,32 In addition, dexmedetomidine has limited effects
on the cholinergic system, which is involved in cognitive function and in the subsequent
development of delirium.33 It has also been proposed that dexmedetomidine may reduce
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delirium by ameliorating pain, an independent risk factor for the development of
delirium.34-37 As such, an integrative review to examine whether use of dexmedetomidine
was associated with a reduction in delirium as compared to other analgesic and sedation
strategies was conducted.
Methods
Our literature search, article selection, and evaluation were guided by PRISMA
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) for quality of
reporting for systematic and meta-analyses.38 A literature search was conducted with
National Library of Medicine Medical Subject Headings (MeSH) terms dexmedetomidine
and delirium. The search was further refined by keywords (elderly, intensive care, critical
care and clinical trial) entered into the electronic search. Studies published between
1986 and 2017 were reviewed by using three electronic databases: PubMed, Scopus
and Embase. Inclusion criteria included: 1) articles written in English; 2) search terms
found in the title or as keywords; 3) study sample defined as adult population; and 4)
delirium as a primary or secondary outcome. Exclusion criteria included: 1) articles
related to the pediatric critical care setting; 2) mixed adult/pediatric studies; 3) case
studies, commentaries, expert consensus, editorials and grey literature; and 4) chronic
or cancer pain populations. The search strategy conducted with a health science
librarian yielded 309 articles, 53 titles and keywords that met inclusion criteria and were
screened for relevancy. Upon further review, 20 articles were retained and evaluated for
scientific rigor of study design, methods and analysis. After reading the full text, four
additional articles were excluded not meeting the inclusion and exclusion criteria, leaving
a total of 16 articles chosen for analysis and review (Figure 2.1). Using the Johns
Hopkins Nursing Evidence-Based Practice Research Appraisal Guidelines,39 the design

31

and quality of evidence of the articles were assigned an evidence level of I, II, III, IV or V
and graded A (high quality) B (good quality) or C (low quality or major flaws) (Table 2.1).
Study Characteristics
The 16 articles selected for review included: seven randomized, double-blind, controlled
studies; four randomized, open label, controlled studies; and five retrospective cohort
analysis studies (Table 2.2). All articles were published in peer-reviewed journals
between 2007 and 2017. For nine studies, delirium was the primary outcome measure.
Delirium was a secondary outcome for seven of the studies. The primary outcome
measurements of these studies were: 1) percentage of time within target Richmond
Agitation-Sedation Scale (RASS) range40; 2) mortality and postoperative major adverse
cardio-cerebral events41; 3) time to randomization and proportion of RASS assessments
in the first 48 hours in the light to deep sedation range 42; 4) time on mechanical
ventilation43; 5) incidence of agitation in the post anesthesia care unit (PACU) 44; 6) inhospital, operative and 1-year mortality45; and 7) mortality and ventilator free days.46 Of
the studies reporting the mean age for the dexmedetomidine group, the sample
population ranged from 55 to 74 years of age.
Identification of Delirium
The Confusion Assessment Method (CAM) and the CAM for the Intensive Care Unit
(CAM-ICU) were most commonly used to identify delirium. These tools screen for
delirium based on four features: 1) acute onset of mental status changes or a fluctuating
course; 2) inattention; 3) disorganized thinking; and; 4) altered level of consciousness.
For delirium to be present, a patient must display features 1 and 2, with either 3 or 4. 47,48
Both the CAM and CAM-ICU have been derived and validated against diagnostic criteria
established by the Diagnostic and Statistical Manual of Mental Disorders (DSM-V),1 the
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“gold standard” for diagnosing delirium. The CAM and CAM-ICU are the most widely
used tools to identify delirium.48
Results
Across studies, there was relative consistency in how delirium was identified. Twelve of
the studies relied on the CAM-ICU for evaluation of delirium; one study utilized a trained
neuropsychiatrist,19 and three studies defined the development of delirium as “the
presence of illusions, confusion, cerebral excitement having a comparatively short
course.”41,45,49 The studies retained for this review were delineated into three patient
subgroups; those: 1) on mechanical ventilation; 2) having had cardiac surgery; and 3)
having had non-cardiac surgery.
Mechanical Ventilation
Shehabi and colleagues (2013)42 evaluated early goal-directed sedation with
dexmedetomidine compared to standard sedation with midazolam and/or propofol. The
results showed dexmedetomidine resulted in an equal portion of patients who
experienced delirium during the study period (38%; p = 0.97). 42 The MENDS
(Maximizing Efficacy of Targeted Sedation and Reducing Neurocognitive Dysfunction) 15
study compared dexmedetomidine and lorazepam. Authors concluded that patients who
received dexmedetomidine had more days alive without delirium and coma compared to
those who received lorazepam (median 7 verses 3 days; p = 0.01). A subgroup analysis
of these data showed no significant difference in the development of delirium between
septic and non-septic patients.16 Following this line of investigation, the DESIRE
(Dexmedetomidine for Sepsis in Intensive Care Unit Randomized Evaluation) trial
prospectively evaluated patients with and without sepsis, 46 and again reported the
incidence of delirium to be not statistically significantly different between groups. 46 Riker
and colleagues40 compared midazolam to dexmedetomidine. The prevalence of delirium
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in patients treated with dexmedetomidine was 54.0% compared to 76.6% in patients
treated with midazolam (22.6% difference, 95% CI: 14% to 33%; p < 0.001).
Cardiac Surgery
Maldonado and colleagues19 compared dexmedetomidine to propofol and midazolam.
The incidence of delirium for the entire study population was 34%, with those receiving
dexmedetomidine just 3%, compared to 50% for propofol, and 50% for midazolam (p <
0.001).19 Wanat and colleagues43 also compared the use of dexmedetomidine and
propofol, however the incidence of delirium (any vs. none) was similar (9.09% vs. 7.52%,
p = 0.747) across both groups. Djaiani and colleagues also reported no statistically
significant difference between patients in receiving dexmedetomidine (16 of 91, 17.5%)
versus propofol (29 of 92, 31.5%) (Odds ratio, 0.46; 95% CI, 0.23 to 0.92; p = 0.028). 50
Li and colleagues studied dexmedetomidine in a placebo-controlled trial, and the
authors found no significant difference between the two groups in the incidence of
delirium, 4.9% (7/142) in the dexmedetomidine group vs 7.7% (11/143) in the control
group (OR; 0.62, 95% CI, 0.23-1.65; p = 0.341). Lastly, Shehabi and colleagues 40
compared dexmedetomidine to morphine-based treatment regimens in the DEXCOM
study (DEXmedetomidine COmpared to Morphine). Of note, this is the only study
retained in this review that evaluates dexmedetomidine against an opioid comparator.
The overall incidence of delirium within five (5) days was 11.7% (35 out of 299 patients)
with 8.6% occurring in the dexmedetomidine group compared to 15% in the morphine
group (RR, 0.571, 95% CI 0.256 to 1.099, p = 0.088). 40 Several retrospective studies by
Fuhai and colleagues41,45,49 have also examined the effect of dexmedetomidine on the
development of delirium in different groups of cardiac surgery patients. All three
investigations found a statistically significant reduction in the incidence of delirium
between dexmedetomidine and non-dexmedetomidine groups.
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Non-Cardiac Surgery
The effect of dexmedetomidine has also been assessed in studies of patients
undergoing non-cardiac surgical procedures. These studies include heterogeneous
surgical patient populations, and they are distinct from the mechanical ventilation
subgroup in that they include a defined surgical period. Yang and colleagues (2015) 44
examined whether dexmedetomidine sedation could decrease agitation and delirium
after free flap maxillofacial surgery. These authors detected that the incidence of
delirium was similar between the dexmedetomidine (5.1%; 2 of 39 patients) and control
(saline) groups (12.5%; 5 of 40 patients; p = 0.432).44 Next, Su and colleagues (2016)51
investigated a prophylactic low-dose dexmedetomidine versus placebo in patients
undergoing abdominal, thoracic, spinal and transurethral surgeries. Postoperative
delirium was observed in just 32 (9%) patients receiving dexmedetomidine compared to
79 (23%) patients receiving placebo (OR, 0.35, 95% CI 0.22 – 0.54; p <0.0001). Deiner
and colleagues52 also studied dexmedetomidine versus placebo in spine, thoracic,
orthopedic, and/or general surgery patients, however they found no statistically
significant difference in post-operative delirium between the dexmedetomidine and
placebo groups.
Discussion
Overview of findings
Across studies, there was significant variability in the timing of administration of
dexmedetomidine including preoperative, intraoperative and postoperative, and sample
populations (e.g., mechanically ventilated patients not following a surgical procedure,
cardiac surgery patients, or other surgical patients). Within the cardiac surgery sample,
there was evidence favoring the use of dexmedetomidine to reduce the incidence of
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delirium, while the mechanically ventilated and non-cardiac surgery samples helped
generate hypotheses to explain the unsuccessful outcomes with administration.
Pre-operative Administration
Pre-operative administration of dexmedetomidine was observed in cardiac surgery
patients as demonstrated by Li and colleagues 53 and a non-cardiac surgery population
as demonstrated by Deiner and colleagues.52 Neither instance resulted in a reduction of
delirium following administration of dexmedetomidine. In both studies, dexmedetomidine
was started upon entering the operating room and continued for either two hours
postoperatively (Deiner et al; infusion rate 0.5 μg · kg -1 · h-1) or until extubation (Li et al;
infusion rate 0.1 μg · kg-1 · h-1). Both studies specifically targeted older adult patients
(aged greater than 68 and 60 years respectively) and were placebo controlled (normal
saline). As such, propofol and or midazolam were allowed for sedation in the treatment
(dexmedetomidine) group. This older adult population presented with additional
vulnerability to the development of delirium associated with the aging process. The
presence of intraoperative general anesthetics, in combination with postoperative
sedation with propofol and or midazolam, may result in blocking the intrinsic properties
of dexmedetomidine thought to prevent delirium. A second consideration for the lack of
efficacy may be due to the short time course of drug administration in the study by
Deiner and colleagues (only two hours postoperatively), and the low infusion rate (0.1 μg
· kg-1 · h-1) in the study by Li and colleagues. Preoperative administration with
concomitant propofol or midazolam appears to reduce the efficacy of dexmedetomidine
in the reduction of postoperative delirium. Large scale clinical trials should be conducted
with higher infusion rates and longer durations of drug administration to see if
preoperative use of dexmedetomidine may be effective in prevention of postoperative
delirium.
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Intraoperative Administration
Intra-operative administration of dexmedetomidine was observed in three cardiac
surgery studies (Maldonado et al.19; Fuhai et al. 201341; and Fuhai et al. 201449); and
one non-cardiac surgery study (Yang et al.44). All three of the cardiac surgery studies in
this group report a decrease in the incidence of delirium (Maldonado et al. 19 Fuhai et al.
201341 and Fuhai et al. 201449), while the one non-cardiac study reported no statistically
significant reduction of delirium (Yang et al.44) after use of dexmedetomidine in the intraoperative period. Dosing across all four studies was similar (0.2 – 0.7 μg · kg-1 · h-1) and
drug administration occurred in all instances 60 minutes prior to the end of surgery and
continued for no more than 24 hours. The total length of surgical time reported by Yang
and colleagues was 399.1  94.6 minutes in the dexmedetomidine group and 402.7 
92.6 minutes in the control group. This total surgical time is significantly longer than
reported in the cardiac surgery study by Maldonado and colleagues (dexmedetomidine
group: 302  106 minutes; control group 306  97 minutes). As in the preoperative
studies, the extended length of time under general anesthesia may have influenced the
efficacy of intraoperative dexmedetomidine in the study by Yang and colleagues. To test
this hypothesis, additional studies would need to evaluate the duration of surgical time in
relation to dexmedetomidine dosing. However, these results do show promise that
dexmedetomidine is effective in reducing the incidence of postoperative delirium in
cardiac surgery patients. An important limitation of this group however, is two of the
cardiac surgery studies are retrospective analyses. Therefore, prospective studies are
still needed to validate this mechanism.
Postoperative Administration
Postoperative administration of dexmedetomidine was observed in four cardiac surgery
studies (Shehabi et al.40; Wanat at al.43; Cheng et al.45 and Djaiani et al.50) and one non37

cardiac surgery study (Su et al.51). The incidence of delirium was reduced in four out of
five studies (three cardiac surgery and one non-cardiac surgery). Patients undergoing
cardiac surgery are at an increased risk of developing delirium due of the complexity of
the surgical procedure and the high risk of postoperative complications.19,41,45,53 First line
therapy for sedation in patients admitted to the cardiac ICU is typically propofol and/or
midazolam. This result is highly suggestive that dexmedetomidine given postoperatively
may be able to overcome the neurochemical milieu of general anesthesia. All studies in
this group used active comparators (morphine, propofol and/or midazolam) which
reduced the administration of these agents in the dexmedetomidine group possibly
contributing to the efficacy of treatment with dexmedetomidine. Sedation in patients
admitted to the cardiac ICU is typically managed with propofol and/or midazolam which
have both been shown to increase rates of delirium. The reduction of these agents may
explain the increased efficacy of dexmedetomidine as the sole sedative agent. Study
drug dosing across studies was similar ranging from 0.1 – 0.7 μg · kg-1 · h-1, titrated to
the desired clinical effect. In the four studies which showed effectiveness of
dexmedetomidine, the time on medication was up to 24 hours. The duration of study
drug infusion was unspecified in the one study in which dexmedetomidine was not
effective in preventing delirium. This study by Wanat and colleagues 43 was a
retrospective investigation which limits the generalizability of its results. The five studies
reported in this cohort represent three randomized clinical trials and two retrospective
investigations. All three of the randomized clinical trials showed superiority of
dexmedetomidine when compared to morphine and propofol in reducing the incidence of
postoperative delirium.
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Mechanical Ventilation
Standard management of sedation in the general ICU typically relies heavily on GABA
receptor agonists such as propofol and benzodiazepines, such as midazolam and/or
lorazepam.2,54,55 Mechanically ventilated patients not following a surgical procedure were
evaluated in five studies (Pandharipande et al. 2009 15; Riker et al.40; Pandharipande et
al. 201016; Shehabi et al.42; and Kawazoe et al.46). Delirium and coma-free days were
decreased in three out of the five studies. In the two studies where the incidence of
delirium was not reduced (Shehabi and Kawazoe), delirium was a secondary endpoint,
thus these studies may not have been adequately powered to detect changes in the
prevalence of delirium. The three studies in which dexmedetomidine was effective in
reducing delirium consisted of two randomized clinical trials, and one retrospective
cohort study. Therefore, additional research is needed to support the use of
dexmedetomidine for sedation not following a surgical procedure.
Aging
Lastly, among the 16 studies, five studies specifically targeted adults aged 70 years and
older (Shehabi et al.40; Djaiani et al.50; Cheng et al.45 ; Deiner et al52; and Su et al.51). The
occurrence of delirium was reduced following usage of dexmedetomidine in four out of
five studies. These studies included four randomized controlled trials with reduction of
delirium as the primary outcome measure40,50-52 and one retrospective cohort analysis
with delirium as a secondary outcome measure.45 This cohort also characterizes three
cardiac surgical studies and two non-cardiac surgical studies. In each of the four studies
in which delirium was reduced following administration of dexmedetomidine, it was
administered in the postoperative setting. In the study by Deiner and colleagues,52 which
did not report a statistically significant reduction in delirium, the drug was administered in
the preoperative setting (these concerns have been discussed above). Taken together,
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these outcomes support that the administration of dexmedetomidine is safe in older
adults, often with the advantageous consequence of decreasing and/or preventing the
development of delirium. Specifically, in older adults undergoing cardiac surgical
procedures, there is compelling evidence to support postoperative sedation with
dexmedetomidine may reduce the incidence of delirium.
Gaps in the Research and Future Directions
Patients included in the cardiac surgery subgroup were admitted to the cardiac ICU
following some type of cardiac surgical procedure, whereas patients in the mechanically
ventilated subgroup may not have undergone a surgical procedure (i.e. admitting
diagnosis sepsis, pneumonia, shock, etc.). The cardiac surgery subgroup, therefore,
reflects a more homogenous patient population as the procedures during and following
cardiac surgery tend to be more routine. However, it also presents greater variability in
study drug administration and is possibly confounded due to exposure to general
anesthesia during surgery. Additionally, some studies used dexmedetomidine for
sedation or prevention of delirium over a short time period. When given later on in the
ICU course or for longer durations dexmedetomidine may not have the same effects.
None of the studies included reports of non-pharmacological interventions as part of
their reduction strategies. Recent evidence supports the promotion of sleep, aiming to
provide at least 4 hours of sleep per night, for the reduction of delirium. 56 Only one study
included in this review evaluated patient’s quality of sleep. Pain management is another
unaddressed concern in this evidence-based review. Only two of the 16 studies reported
pain scores. The short-term consequences of undermanaged pain include higher energy
expenditure and immunomodulation, both of which can contribute to the incidence of
delirium. Sensory stimulation and early mobilization are other facets of the delirium
prevention bundle that were not addressed in the articles included in this review. 56
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Unreported inclusion of some, or all, of these factors may have aided in reduction of
delirium in the presented studies. The lack of this information makes it difficult to assess
if these non-pharmacologic strategies, incorporated in many ICUs, played a role in the
development of the results.
An additional limitation of this work is the lack of studies using age as a control
variable. As noted, the older adult population ( 65 years) is at the greatest risk for
developing delirium. Also, there is no consensus on the duration and timing of drug
administration. Additional studies are needed comparing the duration of infusion. In
accordance with the hypothesis that dexmedetomidine may mimic natural sleep
architecture, studies should also be completed to evaluate day-time versus nighttime
drug administration. If sleep is a potential curative or preventative measure for reducing
the incidence of delirium, nighttime administration of dexmedetomidine may be
advantageous in aligning patients with their natural circadian rhythms to facilitate more
restful and restorative sleep. This mechanism should be evaluated more thoroughly in
randomized clinical studies.
Conclusions
At present, dexmedetomidine administration does not reduce the incidence and/or
duration of delirium uniformly across all patient populations included in this review.
However, there is good evidence to support the administration of dexmedetomidine
during and following cardiac surgical procedures. This finding is in good agreement with
the results of three recent meta-analysis in ICU patients.57-59 In future work, nonpharmacologic interventions, pain management, and quality of sleep need to be included
in these validation studies. Each of these capacities (pain management, sleep, drug
administration) are area’s in which bedside care providers are important stakeholders
and should help drive this research forward. As the population continues to age and the
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incidence of comorbid illnesses grows, addressing the prevention and reduction of
delirium is a timely and imperative objective.
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Figures and Tables

Figure 2.1 PRISMA Diagram
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Table 2.1 Johns Hopkins Evidence Level and Quality Guide
Evidence Levels

Quality Guides

Level I
Experimental study, randomized controlled
trial (RCT)
Systematic review of RCTs, with or without
meta-analysis
Level II
Quasi-experimental study
Systematic review of a combination of RCTs
and quasi-experimental, or quasi-experimental
studies only, with or without meta-analysis

A High quality: Consistent, generalizable
results; sufficient sample size for the
study design; adequate control;
definitive conclusions; consistent
recommendations based on
comprehensive literature review that
includes thorough reference to scientific
evidence

Level III
Non-experimental study
Systematic review of a combination of RCTs,
quasi-experimental and non-experimental
studies, or non-experimental studies only, with
or without meta-analysis
Qualitative study or systematic review with or
without a meta-synthesis
Level IV
Opinion of respected authorities and/or
nationally recognized expert
committees/consensus panels based on
scientific evidence
Includes:
• Clinical practice guidelines
• Consensus panels
Level V
Based on experiential and non-research
evidence
Includes:
• Literature reviews
• Quality improvement, program or financial
evaluation
• Case reports
• Opinion of nationally recognized
experts(s) based on experiential evidence
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B Good quality: Reasonably consistent
results; sufficient sample size for the
study design; some control, fairly
definitive conclusions; reasonably
consistent recommendations based on
fairly comprehensive literature review
that includes some reference to
scientific evidence
C Low quality or major flaws: Little
evidence with inconsistent results;
insufficient sample size for the study
design; conclusions cannot be drawn

Table 2.2 Table of Evidence
Authors/Year/
Country

Study Aim

Pandharipande
et al.1 2007,
United States

Evaluate if
dexmedetomidine
reduces the duration
of delirium and coma
in mechanically
ventilated ICU
patients while
providing adequate
sedation as compared
with lorazepam.

Methodology, Study Design

Sample Characteristics

Major
Findings/Outcomes

Evidence
Level and
Grade

Mechanical Ventilation
Randomized, double-blind, controlled trial
Patients were randomized upon arrival to the ICU.
The study drug was infused as needed until
extubation or for the maximum time allowed (120
hours).
Dexmedetomidine: 0.15 – 1.5 μg · kg-1 · h-1

Mechanically ventilated medical and
surgical ICU patients at 2 tertiary
care centers between August 2004
and April 2006.
Sample size: 106

Dexmedetomidine
patients had more
days alive without
delirium or coma
(median, 7 vs. 3; p =
0.01)

Level I
Grade A

Using a generalized
estimating equation
analysis, the effect of
dexmedetomidine
treatment on delirium
was 24.9% reduction
(95% CI; 16% - 34%,
p <0.001).

Level I
Grade A

Age, Median (Interquartile Range)
Dexmedetomidine 60 (49 - 65)
Lorazepam 59 (45 - 67)

OR
Lorazepam: 1 – 10 mg · h-1

Riker et al.2,
2009, United
States

To compare the
efficacy and safety of
prolonged sedation
with
dexmedetomidine vs
midazolam for
mechanically
ventilated patients.

Delirium assessed using the CAM-ICU.
Prospective, randomized, double-blind, controlled
trial
Patients were randomized with in 96 hours of being
intubated. The study drug was infused as needed
until extubation, after a maximum of 30 days, or at
the discretion of the investigator.
Optional loading dose:
Dexmedetomidine: up to 1.0 μg · kg-1

Medical/surgical ICU patients with
expected mechanical ventilation for
more than 24 hours. Conducted in
68 centers in 5 countries between
March 2005 and August 2007.
Sample size: 375
Age, mean (SD)
Dexmedetomidine 61.5 (14.8)
Midazolam 62.9 (16.8)

OR
Midazolam 0.05 mg · kg-1
Maintenance Infusion Rate Midpoint:
Dexmedetomidine: 0.8 μg · kg-1 · h-1
OR
Midazolam 0.06 mg · kg-1 · h-1
Delirium assessed using the CAM-ICU.
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The prevalence of
delirium was 54%
(132/244) in
dexmedetomidine
treated patients vs.
76.6% (93/122) in
midazolam patients.
(22.6% difference,
95% CI; 14% to 33%,
p > 0.001)

Pandharipande
et al.3, 2010,
United States

Shehabi et al.4,
2013, Australia
and New
Zealand

Evaluate if
dexmedetomidine
compared to
lorazepam would
provide greater
improvements in
clinical outcomes
among septic patients
than among nonseptic patients.

To assess the
feasibility and safety
of delivering early
goal-directed sedation
with
dexmedetomidine
compared with
standard sedation
with midazolam
and/or propofol.

Subgroup analysis of Pandharipande et al.1 in
patients with and without sepsis identified within 48
hours of enrollment.

Adult medical/surgical mechanically
ventilated patients.
Sample size: 103

Patients were randomized upon arrival to the ICU.
The study drug was infused as needed until
extubation or for the maximum time allowed (120
hours).

Delirium assessed using the CAM-ICU.

Age, Median (Interquartile Range)
With Sepsis
Dexmedetomidine 60 (46 - 65)
Lorazepam 58 (44 -66)
Without Sepsis
Dexmedetomidine 61 (50 - 68)
Lorazepam 60 (52-67)

Multicenter, prospective, open label, randomized
controlled trial

Critically ill adults mechanically
ventilated for greater than 24 hours.

Patients were randomized within12 hours of arrival
to the ICU or intubation. The study drug was
infused as needed until sedation was no longer
required or up to 28 days.

Sample size: 37

Early Goal-Directed Sedation
Dexmedetomidine: 0.1 – 1.5 μg · kg-1 · h-1

Early Goal-Directed Sedation 65 (15)

Dexmedetomidine: 0.15 – 1.5 μg · kg-1 · h-1

Age, mean (SD)
Standard Sedation 61.6 (17)

Septic patients
sedated with
dexmedetomidine
had a mean (95% CI)
of 3.2 (1.1 to 4.9)
more delirium/coma
free days than
patients receiving
lorazepam.

Level III
Grade B

However, no
significant difference
was seen between
patients treated with
dexmedetomidine
and lorazepam in
non-septic patients.
An equal portion of
patients experienced
one or more positive
CAM-ICU
assessments during
the study period
(38%; p = 0.97).

Level I
Grade B

The rate of delirium
free days was not
significantly different
between groups (p =
0.17).

Level I
Grade A

Delirium assessed using the CAM-ICU.
Kawazoe et
al.5, 2017,
Japan

To examine whether
a sedation strategy
with
dexmedetomidine can
improve clinical
outcomes in patients
with sepsis
undergoing
ventilation.

Open-label, multicenter randomized clinical trial
Study drug administration occurred upon ICU
admission. The study drug was infused as needed
until sedation was no longer required.
Dexmedetomidine: 0.1 – 0.7 μg · kg-1 · h-1

Patients with sepsis requiring
mechanical ventilation for at least 24
hours.
Sample size: 201
Age, mean (SD)
Dexmedetomidine 68 (14.9)
Control Group 69 (13.6)

Delirium assessed using the CAM-ICU.
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Cardiac Surgery
Maldonado et
al.6, 2009,
United States

Investigated the
effects of
postoperative
sedation on the
development of
delirium in patients
undergoing cardiacvalve procedures.

Randomized, open-label, controlled trial

Patients schedule for elective
cardiac valve operations.

After successful weaning from CPB, patients were
started on one of three randomly assigned,
postoperative sedation regimens. Patients were
extubated while still on the medication and were
kept on the maintenance infusion as deemed
clinically necessary for a maximum of 24 hours.

Sample size: 118
Age, mean (SD)
Dexmedetomidine 55 (16)
Propofol 58 (18)
Midazolam 60 (16)

Using a per-protocol
analysis, the
incidence of delirium
for patients receiving
dexmedetomidine
was 3% (1/30);
propofol 50% (15/30);
and midazolam 50%
(15/30).

Level I
Grade A

The overall incidence
of delirium within 5
days was 11.7% (35
of 299) with 8.6%
occurring in the
dexmedetomidine
group and 15%
occurring in the
morphine group (RR
0.571, 95% CI 0.2561.099, p = 0.088).

Level I
Grade A

Loading dose:
Dexmedetomidine: 0.4 μg · kg-1
Infusion Rate:
Dexmedetomidine: 0.2 – 0.7 μg · kg-1 · h-1
OR
Propofol: 25 – 50 g · kg-1 · m-1
OR

Shehabi et al.7,
2009, Australia
and New
Zealand

To assess the
neurobehavioral,
hemodynamic, and
sedative
characteristics of
dexmedetomidine
compared with
morphine-based
regimen after cardiac
surgery at equivalent
levels of sedation and
analgesia.

Midazolam: 0.5 – 2.0 mg · h-1
Delirium assessed by a trained neuropsychiatrist.
Randomized, double-blind, controlled trial
Study drug infusions were started in the ICU. The
infusion was continued until the removal of chest
drains, when patient was ready to discharge from
ICU, or for up to 48 hours of mechanical
ventilation.

Cardiac surgery patients 60 years of
age or older. Conducted in two
tertiary university affiliated hospitals
between 2004 and 2007.
Sample size: 306
Age, Median (Interquartile Range)
Dexmedetomidine 71.5 (66 – 76)
Morphine 71(65 – 75)

Dexmedetomidine: 0.1 – 0.7 μg · kg-1 · h-1
OR
Morphine: 10–70 g · kg-1 · ml-1
Delirium assessed using the CAM-ICU.
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Fuhai et al.8,
2013, United
States

To determine whether
the perioperative use
of dexmedetomidine
could reduce the
incidence of
complications and
mortality after cardiac
surgery

Retrospective cohort study
Perioperative dexmedetomidine was administered
after CPB and continued for less than 24 hours
postoperatively in the ICU.

Sample size: 1134
Dexmedetomidine: 0.24 – 0.6 μg · kg-1 · h-1
Delirium was assessed by the presence of
illusions, confusion, cerebral excitement having a
comparatively short course.

Fuhai et al.9,
2014, United
States

Wanat et al.10,
2014, United
States

Patients who underwent coronary
artery bypass surgery and coronary
artery bypass or other cardiac
procedures were included.

Age, mean (SD)
Dexmedetomidine 63 (12)
Non-dexmedetomidine 63.5 (11)

This study
retrospectively
investigated the effect
of dexmedetomidine
on outcomes of
patients undergoing
coronary artery
bypass graft (CABG)
surgery.

Retrospective cohort study

Patients undergoing CABG surgery.

Perioperative dexmedetomidine was administered
after CPB and continued for less than 24 hours
postoperatively in the ICU.

Sample size: 724

Comparison of
dexmedetomidine
versus propofol for
sedation in
mechanically
ventilated patients
after cardiovascular
surgery

Retrospective cohort study

Dexmedetomidine: 0.24 – 0.6 μg · kg · h
-1

-1

Age, mean (SD)
Dexmedetomidine 62.9 (11.8)
Non-dexmedetomidine 64.1 (11.4)

Delirium was assessed by the presence of
illusions, confusion, cerebral excitement having a
comparatively short course.

Patients admitted to the ICU after
cardiovascular surgery from January
through June 2011.

Sedation orders were based on individual
physician ordering upon arrival to the ICU.

Sample size: 352
Average Dose
Dexmedetomidine: 0.489  0.13 μg · kg-1 · h-1
Delirium assessed using the CAM-ICU.
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Age, mean (SD)
Dexmedetomidine 63 (14.1)
Propofol 68 (11.2)

The multivariate
model assessing
delirium (5.46%
versus 7.42%;
adjusted odds ratio,
0.53; 95% confidence
interval, 0.37–0.75; p
= 0.0030) was
statistically significant
between the
dexmedetomidine
and nondexmedetomidine
groups.

Level III
Grade B

The adjusted rates of
delirium (adjusted
OR, 0.431; 95% CI,
0.265 to 0.701, p =
0.0007) were
statistically significant
between the
dexmedetomidine
and nondexmedetomidine
groups.

Level III
Grade B

CAM-ICU scores
were reported in 79%
of dexmedetomidine
patients and 84% of
propofol patients (p =
0.411). Incidence of
delirium (any vs.
none) was similar
between both groups
(9.09% vs. 7.52%, p =
0.747).

Level III
Grade B

Cheng et al.11,
2016, United
States

Djaiani et al.12,
2016, Canada

The goal of this
retrospective study
was to investigate the
effects of
perioperative use of
dexmedetomidine on
outcomes for older
patients undergoing
cardiac surgery.

Retrospective cohort study

Dexmedetomidine
sedation after cardiac
surgery would reduce
the incidence of
postoperative delirium

Single-blind, prospective, randomized controlled
trial

Drug infusion was initiated after CBP and
continued for 24 hours postoperatively in the ICU.

Patients underwent coronary artery
bypass graft (CABG) or valve
surgery.
Sample size: 505

Dexmedetomidine: 0.24 – 0.6 μg · kg-1 · h-1
Delirium was assessed by the presence of
illusions, confusion, cerebral excitement having a
comparatively short course.

Age, mean (SD)
Dexmedetomidine 73.6 (6.1)
Non-dexmedetomidine 73.5 (6.2)

Patients undergoing cardiac surgery.
Sample size: 185

Upon arrival to ICU sedation was initiated. The
infusion was continued for a maximum period
of 24 hours.
Loading dose:
Dexmedetomidine: 0.4 μg · kg-1
Infusion Rate:
Dexmedetomidine: 0.2 – 0.7 μg · kg-1 · h-1
OR
Propofol: 25 - 50 μg · kg-1 · m-1
Delirium assessed using the CAM-ICU.
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Age, mean (SD)
Dexmedetomidine 72.7 (6.4)
Propofol 72.4 (6.2)

Results of
multivariate analysis
show that
postoperative delirium
(adjusted OR, 0.350;
95% CI, 0.212-0.578;
p = 0.007) was
decreased
significantly in the
dexmedetomidine
group.
A total of 11 (12.1%)
and 25 (27.1%) in the
dexmedetomidine
and propofol groups
respectively,
developed delirium.

Level III
Grade B

Level I
Grade B

Li et al.13, 2017,
China

The purpose of this
study was to
investigate the impact
of perioperative
dexmedetomidine
administration on the
incidence of delirium
in elderly patients
after cardiac surgery.

Randomized, double-blind, placebo-controlled trial

Patients after cardiac surgery.

In the operating room, study drug infusion was
started once the intravenous access was
established until the end of surgery. After surgery,
study drug infusion was continued until the end of
mechanical ventilation.

Sample size: 285
Age, mean (SD)
Dexmedetomidine 66.4 (5.4)
Control Group 67.5 (5.3)

Loading dose:
Dexmedetomidine: 0.6 μg · kg-1
Infusion Rate During Surgery:
Dexmedetomidine: 0.4 μg · kg-1 · h-1
Infusion Rate Post-Operatively:
Dexmedetomidine: 0.1 μg · kg-1 · h-1

There was no
significant difference
between the two
groups in the
development of
delirium during the
first 5 days following
surgery, 4.9% (7/142)
in the
dexmedetomidine
group vs 7.7%
(11/143) in the control
group (OR; 0.62, 95%
CI 0.23-1.65; p =
0.341)

Level I
Grade A

The incidence of
delirium within 5 days
postoperatively was
similar between the
dexmedetomidine
(5.1%; 2 of 39
patients) and control
(saline) groups
(12.5%; 5 of 40
patients; p = 0.432)

Level I
Grade A

Post-operative
delirium occurred in

Level I
Grade A

Delirium assessed using the CAM-ICU.

Non-Cardiac Surgery
14

Yang et al. ,
2015, China

To determine whether
dexmedetomidine
sedation in the postanesthesia care unit
could decrease
agitation and delirium
after free flap surgery

Prospective, randomized, double-blind, controlled
trial

Patients scheduled for maxillofacial
surgery from June to October 2013.

Infusion of the blinded study drug was started
approximately 60 minutes before the end of
surgery until the operation was completed;
infusions were continued in the PACU until 6:00
AM the next morning.

Sample size: 80
Age, mean (SD)
Dexmedetomidine 50.3 (15)
Control group 50.6 (12.3)

Infusion Rate During Surgery:
Dexmedetomidine: 0.5 μg · kg-1 · h-1
Infusion Rate Post-Operatively:
Dexmedetomidine: 0.2 – 0.7 μg · kg-1 · h-1
OR
0.9% Saline
Delirium assessed using the CAM-ICU.
Su et al.15,
2016, China

To investigate
whether prophylactic

Randomized, double-blind, placebo-controlled trial
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Patients admitted to intensive care
units after non-cardiac surgery.

low-dose
dexmedetomidine
could safely decrease
the incidence of
delirium in elderly
patients after noncardiac surgery.

Infusion was started from study recruitment on the
day of surgery (usually within 1 hour after ICU
admission) until 0800 h on the first day after
surgery.
Dexmedetomidine: 0.1 μg · kg-1 · h-1

Sample size: 700
Age, mean (SD)
Dexmedetomidine 74.3 (6.7)
Control group 74.4 (7.0)

OR

79 (23%) of patients
receiving placebo,
and in 32 (9%) of
patients receiving
dexmedetomidine
(OR, 0.35, 95% CI
0.22 – 0.54; p =
<0.0001)

0.9% Normal Saline
Deiner et al.16,
2017, United
States

To evaluate whether
an intraoperative
infusion of
dexmedetomidine
reduces postoperative
delirium.

Delirium assessed using the CAM-ICU.
Multicenter, double-blind, randomized, placebocontrolled trial
Infusions were started in patients on entering the
operating room and was continued until 2 hours
into recovery.
Dexmedetomidine: 0.5 μg · kg-1 · h-1
OR
0.9 % Saline
Delirium assessed using the CAM-ICU.
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Patients undergoing major elective
non-cardiac surgery.
Sample size: 404
Age, Median (Interquartile Range)
Dexmedetomidine 74 (71-78)
Control group 74 (71-78)

In total 12.2% (23 of
189) of patients who
received
dexmedetomidine
and 11.4% (23 of
201) of patients who
received placebo
experienced delirium.

Level I
Grade A
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Chapter 3
Evaluating a nurse-led intervention for delirium among older adults in the surgical
intensive care unit
Abstract
Background. Delirium, a prevalent condition in hospitalized older adults ( 65 years), is
an acute brain dysfunction characterized by disturbances in attention, awareness and
cognition not explained by a pre-existing neurocognitive disorder. The ICU Liberation
Executing the ABCDEF Bundle Daily (iLEAD) is a nurse-driven protocol aimed at
reducing the severity of delirium in the surgical intensive care unit (SICU) via the
implementation of independent nursing interventions.
Objectives. When nurses routinely assess and manage modifiable risk factors for
delirium (pain; sensory impairment; immobilization; medication administration; surgery,
environment; emotional distress; and sustained sleep deprivation), the number of days
of delirium will decrease and patient outcomes will improve. This retrospective analysis
evaluated the impact of the iLEAD intervention on the number of days with delirium,
length of stay in the SICU, overall hospital length of stay, 30-day readmission rates and
30-day mortality experienced by older adults.
Methods. Employing an observational cohort design, this study compared delirium
outcomes pre- versus post-iLEAD implementation. The sample consisted of 93 patients
admitted to the SICU at the Hospital of the University of Pennsylvania. Outcomes were
evaluated by medical record review.
Results. Rates of delirium screening more than doubled following iLEAD
implementation. Consistent with previous reports, delirium contributed to both SICU and
overall hospital length of stay and 30-day mortality. Other than a trend for improvements
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in rates of 30-day readmissions, no improvement in delirium outcomes were noted for
the patients who received iLEAD delirium-informed care.
Conclusions. This work examined the nurse-management of delirium among older adult
patients admitted to the SICU. Improved patient outcomes, while not statistically
significant, were achievable in the early stages of the iLEAD intervention and may inform
prospective systems-level organizational change. With continued adherence to the
iLEAD intervention, it is hypothesized that outcomes will progressively improve.
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Introduction
Delirium is an acute brain dysfunction characterized by disturbances in attention,
awareness and cognition not explained by a pre-existing neurocognitive disorder.1
Delirium in the intensive care unit (ICU) is common for hospitalized older adult patients
( 65 years) due to the severity of their illnesses, the number of their comorbidities and
their advanced age,1-3 and has been reported to occur in approximately 50% of all
hospitalized older adults.2 The clinical presentation of delirium can be hypoactive,
hyperactive or mixed.1 Notably, the hypoactive form occurs most frequently in older adult
patients, and too often, these patients are overlooked or misdiagnosed as having
depression or dementia as opposed to delirium. 2 Aging itself has also been described as
a risk factor for developing delirium.4-7
Older adults consume nearly 60% of all ICU days 8 and are predisposed to higher
rates of delirium than adults under the age of 65 years. For these older adults, delirium
poses a significant health threat.3,5,9,10 Delirium has been associated with longer ICU and
hospital stays,9,11-13 increased health care costs and poorer outcomes related to
readmissions14-16 and increased mortality.9,12,17-19 Delirium has been identified as one of
six leading causes of injuries associated with hospitalization in older adults.20
In a study of 304 older adult patients admitted to the medical ICU, the typical length
of ICU stay was five days, with an average of three days of delirium. 12 Added costs per
hospitalization attributable to delirium range from $16,303 to $64,421 per patient.14 A
one-year study of hospitalized adults 70 years or older, reported 109 patients (13.0%)
developed delirium while 732 did not.15 The subsequent health care costs associated
with delirium suggested that patients with delirium were more than 2.5 times as costly
than patients without delirium.15 In that Medicare and Medicaid reimbursements are tied
to rates of 30-day readmissions,21 some delirium-related costs are attributed to
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readmitted patients with delirium. Readmissions alone also have also been associated
with unfavorable patient outcomes in patients with delirium.16 Finally, delirium has been
reported to be an independent marker for increased mortality in older medical inpatients
both 6- and 12-months after hospital admission.9,18 Because delirium can be a lifethreatening condition for older adults,2 limiting its occurrence and severity is imperative
to improving patient outcomes. To date, there are few studies that have specifically
examined the effect of delirium on outcomes of older adults admitted to the surgical
intensive care unit (SICU).
The 2013 revised Society for Critical Care Medicine (SCCM) Clinical Practice
Guidelines for Management of Pain, Agitation, and Delirium 22 recommend routine
monitoring of sedation, pain and delirium for all patients in the ICU. The SCCM’s ICU
Liberation Collaborative initiative offers a broad program to enable the application of
these guidelines across hospital systems.23-26 ICU Liberation uses a set of interventions
known as the “ABCDEF Bundle” to guide execution of their recommendations. The
elements of ABCDEF bundle individually and collectively aim to reduce delirium, pain,
agitation and the long-term negative health consequences of delirium in adult ICU
patients.24,25,27,28 The first large scale evaluation of the ABCDEF bundle included over
15,000 adult patients (18+ years of age) from 68 ICUs (including mixed medical/surgical,
medical, surgical/trauma, neurological, cardiac/surgical and surgical). Complete
performance of the ABCDEF bundle was associated with a lower likelihood of next-day
mechanical ventilation, decreased rates of delirium, reduced ICU readmissions and
decreased 7-day mortality rates.26
Utilizing the principles of systems science, which encompass improving quality,
outcomes, and costs of health care delivery for patients and populations within systems
of medical care,29 The Hospital of the University of Pennsylvania created the ICU
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Liberation Executing the ABCDEF Bundle Daily (iLEAD), a nurse-driven intervention
designed by an interprofessional team to implement the ABCDEF bundle and reduce the
consequences of delirium in the ICU within their health system. A study was undertaken
to compare (1) days of delirium, (2) SICU and (3) hospital length of stay, (4) 30-day
readmission rates and (5) 30-day mortality in cohorts of older adults in the SICU prior to
and following implementation of the iLEAD intervention. A conceptual model (Figure 3.1)
illustrates the relationships of risk factors outlined in the iLEAD protocol for delirium to
the clinical outcomes of interest. It is postulated that the assessment of non-modifiable
risks for delirium and management of modifiable risks will lead to fewer days of delirium
and improved patient outcomes. When nurses routinely assessed and managed
modifiable risk factors for delirium (i.e., implement the iLEAD intervention), it was
hypothesized that patient outcomes would improve.
Methods
Design
A retrospective observational pre- and post-intervention cohort study was designed to
examine delirium-related outcomes in older adult patients in the SICU which might have
contaminated the care received prior to formal implementation. All data were extracted
from the electronic health record (EHR). The primary patient outcomes of this
investigation were: days of delirium; SICU length of stay in days; hospital length of stay
in days; rates of 30-day readmissions and rates of 30-day mortality. The study was
approved by the University of Pennsylvania Institutional Review Board with exempt
status and waiver of informed consent. Study design and reporting conformed with
criteria outlined in the STrengthening the Reporting of OBservational studies in
Epidemiology (STROBE) guidelines.30
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Setting and Sample
Study participants were selected from a 24-bed surgical critical care unit at a 795-bed
urban academic medical center. Consecutive patients 65 years or older admitted to the
SICU between March 15 and August 15, 2017 were screened for inclusion in the preiLEAD implementation cohort. These patients were compared to a similar cohort of
patients admitted to the same SICU between March 15 to August 15, 2018, representing
the post-iLEAD implementation cohort. The iLEAD intervention was implemented in
January 2018. These cohorts were intentionally selected with several factors in mind.
First, the two cohorts were sampled during the same 6-month calendar periods,
accounting for differences in SICU admission by time of year. Second, March was
chosen as the start date to reflect sufficient duration from the start of the iLEAD
implementation in January, so compliance rates to the intervention would be sufficiently
high. The pre-iLEAD intervention cohort were admitted before any iLEAD planning or
education occurred. During the post-implementation cohort study period, the
interventions for Awake and pain free, spontaneous Breathing trials, Consideration of
Analgesia and Sedation and Delirium were fully implemented, however interventions for
Exercise and Family engagement were still being introduced to the nursing workflow.
Inclusion criteria were; age  65, English speaking, admitted to the SICU for >24
hours, and having screened positive for delirium during the first seven days of ICU stay.
Patients were excluded if they had an admitting diagnosis related to neurological or
central nervous system injury; for patients readmitted to the SICU, only the index
admission was evaluated. Patients not evaluated for delirium using the confusion
assessment method for the intensive care unit (CAM-ICU) between day 1 and day 7
during their admission to the SICU were also excluded. As illustrated in Figure 3.2, the
pre-implementation 2017 sampling pool contained 101 patients, and the post62

implementation 2018 sampling pool, 172 patients. Of the total sample, 37 and 56
patients screened positive for delirium in the 2017 and 2018 cohorts respectively.
Intervention
The iLEAD intervention is a nurse-driven protocol aimed at reducing delirium in the ICU.
As described above, it incorporates a set of interventions designed to coordinate care,
with a specific focus on delirium, as a component of the overall care patients receive.25
Specifically, upon admission to the SICU, the nursing staff reviewed a patient’s medical
history for relevant delirium risk factors (age, history of cognitive impairment, immobility,
audio or visual impairments, history of alcohol use, history of delirium, etc.). Delirium
assessments (CAM-ICU) were conducted twice daily (AM and PM) beginning upon
admission. Patients with a positive CAM-ICU assessment were evaluated for new
infections, or cardiac or neurological events that may explain the change in their mental
status. Inpatient and home medications were also reviewed to assess for medications
likely to induce delirium, such as opioids and benzodiazepines. For those patients who
screened positive for delirium, nurses initiated at least two independent nonpharmacological interventions selected from a menu of interventions based on the risk
factors identified. Additional engagement with the interdisciplinary team was utilized to
identify possible causes of delirium and treatment approach. Delirium was continually
reassessed with the CAM-ICU every 12 hours to monitor for response to the
interventions.
Measures
Delirium. The primary study outcome was the number of days of delirium calculated
using the highly reliable and well-validated CAM-ICU assessment tool.31-33 Reliability for
the CAM-ICU has been established against the DSM-V diagnostic criteria for delirium
(interrater reliability kappa = 0.79-0.96).31 Compared with a reference standard
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(psychiatrist) diagnosis of delirium, the CAM-ICU used by nursing staff had sensitivity
estimates of 93-100% and specificity of 89-100%.31 The CAM-ICU recognizes delirium
based on four features: 1) acute onset of mental status changes or a fluctuating course;
2) inattention; 3) disorganized thinking; and 4) altered level of consciousness. 32,33 For
delirium to be scored as present, a patient must display both a change in mental status
and inattention, along with either disorganized thinking or altered level of
consciousness.32,33 The CAM-ICU was completed and scored by trained nursing staff
every 12 hours. Each assessment generated one of four possible results; positive,
negative, unable to assess (comatose), or no test performed. One day of “no delirium”
was defined as either two negative CAM-ICU assessments, or one negative and one
unable to assess evaluation in a 24-hour period. One day of “delirium” was defined as
one positive CAM-ICU screening in a 24-hour period. The number of days of at least one
positive CAM-ICU screen were calculated beginning at the time of SICU admission
through SICU discharge or up to 7 days. Delirium that emerges beyond 7 days may be
related to an underlying medical abnormality or complications, and therefore not
representative of ICU delirium.34,35
Length of SICU Stay. SICU length of stay was calculated beginning at the time a
patient was admitted to the SICU until they left the SICU.
Length of Hospital Stay. Hospital length of stay was measured beginning at hospital
admission until discharge.
30-day Readmission Rates. Readmission rates were counted as being readmitted to
the hospital for any cause within the 30 days after discharge from a hospitalization. Due
to the limitations of the Penn Medicine EHRs, only readmissions to in-system hospitals
are captured.
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30-day Mortality Rates. Mortality rates were counted as a death occurring within 30
days of hospital admission; deaths could be for any cause and occur in the hospital or
after discharge.
We also used the EHR to ascertain clinical and demographic data that were used as
covariates. These included age, sex, race, use and duration of mechanical ventilation,
Richmond Agitation-Sedation Scale (RASS) scores, and admitting medical diagnosis.
Admitting diagnoses were utilized as a proxy measure for severity of illness.
Data Analysis
Descriptive statistics (mean, standard deviation, median, range and percentages) were
produced to describe and compare sample characteristics of the pre- and postimplementation cohorts using Student’s t-tests for independent groups for continuous
variables and chi-square (𝜒2) tests for categorical variables. Fisher’s exact test was used
for assessment of categorical variables where the cell counts were less than 5. Data
were closely examined for any systematic patterns of missingness. P-values of 0.05 or
less were considered to indicate statistical significance.
Cox Proportional Hazards Regression models were conducted using the PHREG
procedure in SAS to assess cohort (study year) as a predictor of SICU and hospital
length of stay while accounting for both censored and non-censored data. The PHREG
procedure is widely used in analyzing the effect of explanatory variables on time-toevent variables. Patients who died during their SICU stay or had a SICU stay longer than
30 days were classified as censored observations, indicating that they are not assessed
as a true SICU discharge event. Similarly, patients who died during their hospital stay or
had a hospital stay longer than 60 days were classified as censored observations.
Analyses were adjusted for age, sex, race, RASS, use of mechanical ventilation and
admitting diagnosis. The four most prevalent admitting diagnosis were included as
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covariates (neoplasms, diseases of circulatory system, diseases of digestive system and
symptoms, signs & abnormal labs) to control for the effects of medical condition on the
efficacy of the intervention. Kaplan-Meier survival curves were produced for graphical
presentation of these time-to-event analyses. As a preliminary assessment, Cox
Proportional Hazards Regression models were also used to compare SICU and hospital
length of stay between patients with and without delirium across both study years.
Chi square tests were used to evaluate the association between cohort (study year)
and 30-day readmissions, as well as 30-day mortality. Adjusted logistic regression
analyses were then conducted and included age, sex, race, RASS, use of mechanical
ventilation and admitting diagnosis as covariates. As a preliminary assessment, chi
square tests were used to compare readmission and mortality rates between patients
with and without delirium across both study years.
Results
In total, 653 patients were admitted to the SICU between March 15 and August 15, 2017
and 630 patients were admitted between March 15 and August 15, 2018. After screening
for inclusion and exclusion criteria, 101 patients in 2017 and 172 patients in 2018 were
evaluated; of these, 37 patients in 2017 and 56 patients in 2018 screened positive for
delirium, thus comprised the pre- and post-implementation cohorts. Demographically,
the cohorts were comparable (Table 3.1) with the exception that patients with delirium in
the 2018 cohort received more hours of mechanical ventilation during their SICU stay (p
= 0.032).
Outcomes of Patients with and without Delirium
To validate previously described consequences of delirium, preliminary assessments
were performed to compare patients with and without delirium in each cohort. As
expected, Figure 3.3 reflects poorer outcomes for patients with delirium compared those
66

without delirium. The results were unchanged in the adjusted models. The unadjusted
preliminary models are described as follows:
SICU Length of Stay. In both cohorts (Figure 3.3, A and B), delirium exhibited a strong
association with SICU length of stay (2017 𝜒2 = 21.1942, Hazard Ratio (HR): 0.394, p <
0.0001: 2018 𝜒2 = 40.3134, HR: 0.316, p < 0.0001). Three patients in 2017 and eight
patients in 2018 were censored due to either death or a SICU stay longer than 30 days.
Hospital Length of Stay. Similarly, delirium exhibited a strong association with overall
hospital length of stay (Figure 3.3, C and D) in 2017 (𝜒2 = 4.2657, HR: 0.649, p =
0.0389) and 2018 (𝜒2 = 26.2117, HR: 0.436, p < 0.0001). Eight patients in 2017 and 15
patients in 2018 were censored due to either death or a hospital stay of longer than 60
days.
Readmissions. No association between delirium and 30-day readmissions in 2017 (𝜒2 =
0.0004, p = 0.9833) or 2018 (𝜒2 = 0.0076, p = 0.9304) were noted (Figure 3.3, E). Of
patients with delirium in 2017, 18.92% were readmitted within 30 days of hospital
admission compared to 18.75% of patients without delirium. In 2018, 14.29% of patients
with delirium were readmitted within 30 days of hospital admission, compared to 13.79%
of patients without delirium.
Mortality. With respect to 30-day mortality (Figure 3.3, F), in 2017, 16.22% of patients
with delirium died within 30 days of hospital admission, compared to 3.13% of patients
without delirium (𝜒2 = 5.5092, p = 0.0189). In 2018, 16.07% of patients with delirium died
within 30 days of hospital admission, compared to just 3.45% of patients without delirium
(𝜒2 = 8.6133, p = 0.0033).
Summary of CAM-ICU Assessments
To illustrate adherence to the iLEAD intervention, the daily results of the CAM-ICU
assessments were evaluated (Table 3.2). The number of days with a positive CAM-ICU
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assessment was similar between the 2017 and 2018 cohorts (p = 0.7200). Notably, the
number of days of a negative CAM-ICU assessment (p = 0.0178) and the number of
days where no test was performed (p < 0.001) were statistically different between study
year, reflecting the nurse’s uptake of the iLEAD intervention. The number of days with
coma (p = 0.8873) remained similar between cohorts.
Days of Delirium
The incidence of delirium (37% vs. 33%, p = 0.511) and the average number of days of
delirium (p = 0.1660) did not vary significantly by study year (Table 3.1).
SICU Length of Stay
Pre-iLEAD implementation, the median length of stay in the SICU for patients with
delirium was 7 days compared to 8 days for patients following iLEAD implementation (p
= 0.7499) (Table 3.1). Among the 2017 cohort, 51.35% of patients with delirium had
been discharged from the SICU by one week, compared to 43.39% among the 2018
cohort. Within the 2017 cohort, 96.29% of patients with delirium had been discharged
from the SICU after 30 days, compared to 100% in the 2018 cohort (Figure 3.4, A).
Study year was not found to be a significant predictor of SICU length of stay (𝜒2 =
0.3403, HR: 0.881, p = 0.5597). After adjusting for covariates of interest, study year
remained a nonsignificant predictor of SICU length of stay (𝜒2 = 1.6655, HR: 0.770, p =
0.1969).
Hospital Length of Stay
For patients with delirium, the median length of stay in hospital was 15 days in 2017
compared to 17.5 days for patients in 2018 (p = 0.1909) (Table 3.1). Among the 2017
cohort, 13.51% of patients had been discharged after one week, compared to just 1.77%
of patients in the 2018 cohort. After 30 days, 79.76% of the 2017 cohort had been
discharged, compared to 59.98% in the 2018 cohort (Figure 3.4, B). Study year was not
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found to be a significant predictor of hospital length of stay (𝜒2 = 2.299, HR: 0.695, p =
0.1294). After adjusting for covariates of interest, study year was significant predictor of
hospital length of stay (𝜒2 = 4.4103, HR: 0.618, p = 0.0357) favoring the 2017 cohort.
30-day Readmissions
In the 2017 cohort, 18.92% of patients with delirium were readmitted within 30 days of
hospital admission compared to 14.29% in the 2018 cohort. Despite this trend for
decreased 30-day readmissions (Figure 3.4, C), study year did not exhibit a significant
association with hospital readmission (𝜒2 = 0.3535, p = 0.5521). After adjusting for
covariates of interest, study year remained not a significant predictor of readmission
rates (𝜒2 = 0.12, p = 0.7336).
30-day Mortality
Rates of 30-day mortality were essentially unchanged following the iLEAD intervention;
in the 2017 cohort, 16.22% of patients with delirium died within 30 days of hospital
admission, compared to 16.07% in the 2018 cohort (Figure 3.4, C). Study year did not
exhibit a significant association with 30-day mortality (𝜒2 = 0.0003, p = 0.9852). Similarly,
after adjusting for covariates of interest, study year was not a significant predictor of
readmission rates (𝜒2 = 0.23, p = 0.6289).
Discussion
Delirium is a significant and costly problem for older adults in the ICU. It is commonly
under-recognized and undertreated, and the consequences are not only evident in
length of ICU and hospital stay, but in the more worrisome outcomes of 30-day
readmissions and mortality. Empirical evidence for independent nurse-led interventions
to mitigate the development and duration of delirium is accumulating and this evaluation
of the iLEAD intervention contributes to this body of knowledge. In this study, patient-
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level outcomes attributable to delirium in older adults admitted to the SICU were
examined prior to and following the implementation of the iLEAD intervention.
These data support that delirium contributes to both SICU and overall hospital length
of stay, and to 30-day mortality in older patients admitted to the SICU. No differences in
30-day hospital readmission rates were observed in this sample between those with and
without delirium. Increased ICU length of stay was previously reported in a prospective
cohort study of 261 patients admitted to the medical ICU in which 125 patients (48%)
experienced at least one episode of delirium. Patients who experienced delirium had a
29% greater risk of remaining in the ICU (compared to patients who never developed
delirium) even after adjusting covariates (HR: 1.29; CI: 0.98-1.69, p = 0.07).36 A similar
study performed to determine the effects of delirium on length of hospital stay,
concluded in-hospital delirium (36 of 359 patients) was an important predictor of longer
hospital stay. The median length of stay for patients with delirium was 16.5 days
compared to 7.5 days for patients without delirium (difference 9 days). 37 With respect to
mortality, a cohort study of 275 mechanically ventilated patients concluded that 50% of
patients who experienced delirium during their ICU stay died within one-year posthospitalization,9 supporting similar studies that reported increased mortality following an
episode of deliruim.12,18 The SCCM ICU Liberation Collaborative also reported that
implementation of the ABCDEF bundle was associated with a decreased rates of
delirium and a lower likelihood of 7-day mortality.26
The unchanged 30-day hospital readmission rates observed in this study were
somewhat surprising in that the literature has supported an association between delirium
and hospital readmissions. For example, Eide and colleagues examined 136 patients
aged 80 years or greater and evaluated the influence of delirium on 30-day readmission
rates in patients undergoing cardiac surgery. Delirium was identified in 76 (56%)
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patients; 24 out of 30 (80%) patients who were readmitted within 30 days experienced
delirium.17 The lack of group differences in 30-day readmission rates in this sample may
be explained by other factors such as severity of illness, or complications of the disease
process, and not delirium.
No improvement in delirium outcomes were noted for the cohort of patients who
received iLEAD delirium-informed care, other than a trend for improvements in rates of
30-day readmissions (from approximately 19% in 2017 to 14% in 2018). There are
several potential reasons why the iLEAD intervention did not demonstrate effectiveness.
Delirium was more frequently identified in the post-implementation cohort, and therefore
the poor outcomes associated with delirium were more likely to be detected, potentially
confounding the effect of the iLEAD intervention. While the typology of delirium was not
captured in this study, patients with hyperactive delirium exhibit restlessness and
agitation whereas those with hypoactive delirium generally present as lethargic or
sedated and respond slowly to questions or show little spontaneous movements. It is
possible that the primary subtype of delirium reported in the pre-implementation cohort
was mainly hyperactive, as this type of delirium is readily visible as compared to
hypoactive delirium which is more difficult to detect and more common in older adults.
Consequently, while the iLEAD intervention did not show decreased length of stay
for patients with delirium in the post-implementation cohort, patients with delirium in the
pre-implementation cohort may have been more likely to be discharged before complete
recovery from delirium due to lack of education and training. Increased detection rates
for hypoactive delirium in the post-implementation cohort likely contributed to the
increased SICU length of stay. Literature suggests that bundled interventions, such as
the iLEAD protocol, are more likely to reduce the incidence of delirium and provide less
robust evidence to support decreasing severity or duration of delirium.38 Alternatively, it
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is important to consider that undetectable differences between the pre- and postimplementation cohorts may exist.
Interestingly, 30-day readmissions were not associated with SICU delirium either by
study year or presence of delirium. This suggests that readmissions are related to other
factors such as severity of illness, or complications of the disease process, and not
delirium. Readmissions are both a clinical and financial problem. The Center for
Medicare and Medicaid Services (CMS) began penalizing hospitals for 30-day
readmissions starting in 2012.16 According to CMS, the national rate of 30-day all-cause
readmissions observed for patients aged 65 and above in 2013 was 16.2%. 39 The
average cost of a readmission for this age group for any given cause was $13,800 (U.S.
dollars) for those patients on Medicare.39 A portion of these costs are likely attributed to
patients with delirium being re-admitted to the hospital. In other reports of the literature,
little evidence is available describing the impact of days of delirium on hospital
readmissions, a key driver of healthcare costs. The downward trend observed in 30-day
hospital readmissions in this study is nonetheless favorable, and perhaps with a greater
number of patients receiving iLEAD-informed care, these trends will reach significance.
In both cohorts, rates of mechanical ventilation use among patients with delirium
were comparable (65% vs 71%, p = 0.504) as were levels of sedation (RASS) (p =
0.1198). Unexpectedly, patients in the post-implementation cohort spent a greater
number of hours ventilated (66 hours, p = 0.032) than patients in the pre-implementation
cohort (45 hours). To maintain compliance and comfort for patients on the ventilator,
sedative medications, such as propofol and benzodiazepines, are typically used. These
medications have potentially psychoactive effects on the central nervous system and
have been associated with the development of deliruim. 40-46 Greater exposure to these
deliriogenic medications administered secondary to mechanical ventilation in the post72

implementation cohort may have precluded noting appreciable effects of the iLEAD
intervention. The results from the SCCM ICU Liberation Collaborative reported that
implementation of the ABCDEF bundle was associated with a decreased rates of
mechanical ventilation,26 thus once the iLEAD intervention achieves full strength, these
results may continue to improve.
Contemporary guidelines, and the iLEAD intervention, promote lighter sedation
targets (RASS goals) to minimize the negative consequences of increased exposure to
deliriogenic sedatives.22 In critical care patients, literature suggests that maintaining a
deep level of sedation is associated with increased ICU length of stay, longer duration of
mechanical ventilation, and acquired weakness due to immobility. 47 A goal of the iLEAD
intervention is to reduce the time a patient spends on the ventilator, incorporating the
assistance of respiratory therapists, and spontaneous breathing trials. So, while all
stakeholders may actively engage in the success of the iLEAD intervention, systems
level factors related to respiratory therapist availability may explain some potential
shortcomings of implementation. More research is needed to understand the
interprofessional team dynamics to achieving successful outcome for these delirious
patients.
Admitting diagnoses were utilized as a proxy for severity of illness measures, as
more traditional measures of illness severity (i.e., Acute Physiologic Assessment and
Chronic Health Evaluation II (APACHE II) scores) were not exportable for analysis.
Overall the two cohorts were comparable (p = 0.232) with respect to medical diagnosis
on admission. Historically, patients who develop delirium are likely to be more critically ill
than non-delirious patients.9,48 Therefore, it is possible that improved outcomes were not
present due to unmeasured differences related to severity of illness between the two
cohorts not captured by admitting diagnosis. Utilizing only the admitting diagnosis did not
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allow for changes in medical status and comorbidities developed during the course of
the SICU stay to be included in the analysis. These may present additional factors to
evaluate in prospective investigations.
Following iLEAD, the number of days where no CAM-ICU assessment was
documented was drastically reduced. These results suggest that uptake of the
intervention was high and support the analyses of the effect of iLEAD on delirium
outcomes. Importantly, while the duration of delirious episode and number of delirious
patients was similar per group, the number of patients with delirium-free/coma-free days
(p = 0.0178) in 2018 increased significantly. Although this is primarily reflective of
increased rates of screening, it allows the iLEAD team to understand delirium outcomes
more fully among patients in the SICU. Literature proports delirium rates of
approximately 50% in ICU populations,2 however the incidence in the pre and post
iLEAD cohorts were 37% and 33% respectively, suggesting that overall rates of delirium
in this population are well below the reported standard. With continued fidelity to the
iLEAD intervention, we postulate that rates and duration will continue to decrease.
As noted, implementation of the iLEAD protocol does not direct the nurse to utilize
specific delirium interventions, rather allows them to choose from a menu of suggested
interventions. Consequently, the lack of iLEAD effects may be related to nurses
choosing fewer or less effective activities. At the time of data collection, the individual
elements delivered were not captured in the EHR. Furthermore, the entire ABCDEF
bundle had not yet been implemented. The interventions for early mobility (E) and family
engagement (F) were not yet introduced during the study period. As these elements
become implemented, patient outcomes may continually improve.
The results the SCCM ICU Liberation Collaborative shows that implementation of the
ABCDEF bundle can improve patient and health system-level outcomes. These results
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should embolden HUP iLEAD team; with more time and enriched implementation,
patient and systems-level outcomes in the SICU, and across all ICU’s implementing
iLEAD across Penn Medicine, should continue to improve.
Limitations
Being an observational cohort study, patients were not randomized to receive the iLEAD
intervention, thus subject to the threats of selection bias. The control group was
historical, thus changes over time other than iLEAD implementation may have
accounted for the findings. In addition, data collection was limited to that available in the
EHR, and inconsistencies in the accuracy of the documentation is another limitation. Any
conclusions drawn by this study regarding the contributions of the specific nursing’s
interventions implemented will require prospective validation in future studies. Lastly,
because this study was conducted within a single SICU, the outcomes may not be
immediately exportable to other health systems. It is possible that the patient populations
and baseline processes of care for delirium management may not be generalizable to
other hospitals and health systems.
Future Directions
Literature that specifically addresses delirium management interventions for older adults
admitted to the SICU is limited and primarily focuses on comparing pharmacologic
approaches. This paper is one of the first to evaluate the patient-centered delirium
outcomes following implementation of the nurse-led iLEAD intervention in the SICU. This
analysis highlights the contributions of nurses to champion this effort by evaluating the
assessment, management and treatment of patients with delirium by utilizing evidencebased nurse-initiated interventions chosen from a validated list of options. The results of
this study warrant prospective evaluation of the specific nurse-led iLEAD interventions
employed in this study.
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Conclusions
Importantly, this work examines the management of delirium among older adult patients
admitted to the SICU. To date, few studies have specifically examined this patient
population. These results add to the growing body of literature on how to best care for an
aging patient with delirium in the critical care setting. Overall, measurable patient
outcomes were achievable in the early stages of the iLEAD intervention and may inform
prospective systems-level organizational change.
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Figures and Tables

Figure 3.1 Conceptual Model of the Effects of iLEAD on ICU Delirium
This conceptual model illustrates the relationships of risk factors outlined in the iLEAD
protocol for delirium to the clinical outcomes of interest. When nurses implement the
iLEAD intervention, it was hypothesized that patient outcomes (days of delirium, length
of stay, readmissions and mortality) would improve.
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Figure 3.2 Study Sample Consort Diagram
Consort style diagram illustrating the inclusion and exclusion criteria used to evaluate
the pre- and post-implementation cohorts. The 2017 sampling pool contained 101
patients and the post-implementation 2018 sampling pool, 172 patients. Of the total
sample, 37 and 56 patients screened positive for delirium in the 2017 and 2018 cohorts
respectively and were included in the analysis.
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Figure 3.3 Outcomes in Delirious and Non-Delirious Patients
A) ICU Length of Stay 2017 B) ICU Length of Stay 2018. C) Hospital Length of Stay
2017. D) Hospital Length of Stay 2018. E) 30-Day Readmission Rates. F) 30-Day
Mortality Rates.
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Figure 3.4 Pre-implementation (2017) and Post-implementation (2018) Outcomes
of Patients with Delirium
A) ICU Length of Stay. B) Hospital Length of Stay. C) 30-Day Readmissions and
Mortality.
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Table 3.1 Characteristics of Sample

Characteristics
Number of Patients

2017
N=101
No Delirium
Delirium
64
37 (37%)

2018
N=172
No Delirium
Delirium
116
56 (33%)

p-value#
0.511

Age (years), median (range)

72 (65-92)

76 (65-91)

72 (65-92)

73 (65-88)

0.1278

Sex (male), N (%)

40 (63%)

22 (59%)

75 (65%)

33 (59%)

0.959

81 (47 – 129)

77 (50-120)

80 (45-133)

81 (44-172)

0.2457

Race
Asian
Black or African American
Hispanic
Unknown
White
Other

1
9
0
1
53
0

0
4
1
5
25
2

1
9
1
15
90
0

0
7
0
6
42
1

Mechanical Ventilation %
median hours (range)

30%
19 (2-168)

65%
45 (7-168)

25%
18 (1-168)

71%
66 (9 -168)

0.504
0.0320*

RASS, median (range)

0 (-3 to 1)

-1 (-3 to 1)

0 (-4 to 0)

-1 (-2 to 0)

0.1198

3 (2,23)

7 (2, 44)

3 (2,23)

8 (2, 41)

0.7499

10.5 (3,139)

15 (3, 89)

9 (2,58)

17.5 (5,83)

0.1909

--

2.14 ± 1.4

--

2.60 ± 1.7

0.1660

Weight (kg), median (range)

0.593

ICU Length of Stay, median (range)
Hospital Length of Stay, median
(range)
Days of Delirium, mean ± sd
Admitting Diagnosis
(ICD-10-CM Codes)
A00-B99 Infectious and parasitic
diseases
C00-D49 Neoplasms
E00-E89 Endocrine, nutritional and
metabolic disease
H60-H95 Diseases of ear and
mastoid process
I00-I99 Diseases of circulatory
system
J00-J99 Diseases of respiratory
system
K00-K95 Diseases of digestive
system
L00-L99 Diseases of the skin and
tissue
M00-M99 Diseases of
musculoskeletal system
N00-N99 Diseases of genitourinary
system
Q00-Q99 Congenital
malformations/abnormalities
R00-R99 Symptoms, signs &
abnormal labs
S00-T88 Injury, poisoning & other
external causes
Z00-Z99 Factors of health status

0.232
3

1

2

5

0.232

15

6

27

9

0.985

0

1

1

0

0.398

1

1

1

0

0.398

4

3

16

11

0.128

1

3

3

0

0.06

18

10

27

14

0.827

2

0

0

0

--

3

2

1

2

1.0

3

2

4

1

0.561

0

1

0

0

0.398

10

6

25

11

0.676

3

1

6

3

1.0

1

0

2

0

--

*indicates statistical significance. #p-values reflect comparison of patients with delirium between 2017 and
2018.
Abbreviations: (sd) standard deviation; (kg) kilograms; (ICD-10-CM) International Classification of Diseases,
Tenth Revision, Clinical Modification.
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Table 3.2 Daily CAM-ICU Assessments
CAM-ICU Assessment Values
Positive
No Test Performed
Negative
Unable to Assess (Coma)

2017
0.78 ± 1.33
1.1 ± 1.4
2.45 ± 1.66
0.29 ± 0.79

*indicates statistical significance.
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2018
0.85 ± 1.56
0.45 ± 0.65
2.94 ± 1.69
0.27 ± 0.77

p-value
0.7200
<0.001*
0.0178*
0.8873
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Chapter 4
Evaluating the relationships among pain, opioid analgesic administration and the
onset of delirium in older adults in the surgical intensive care unit
Abstract
Background. Analgesics are among the most commonly administered medications to
patients in the surgical intensive care unit (SICU). Literature suggests that that both
untreated pain and pain management with opioids are each independent precipitating
factors for the development of delirium. However, there is limited and mixed evidence to
support these assumptions, particularly among older adults in the SICU.
Objectives. This cross-sectional secondary data analysis evaluates the relationships
among pain severity, its management with opioids, and the onset of delirium in older
adult patients admitted to the SICU.
Methods. A convenience sample of consecutive patients aged 65 or greater admitted to
the SICU over a 5-month period were examined (n = 172). Averaged 24-hour pain
severity scores and opioid exposure were extracted from the electronic health record
and examined with respect to the onset of next day delirium.
Results. Opioids (chi-square [𝜒2], 12.60, P = .0004), but not pain (𝜒2, 3.61, P = .0573)
were significant in predicting next-day delirium status. Controlling for pain severity,
patients exposed to opioids exhibited odds of developing delirium were 2.5 times those
of patients not exposed to opioids (95% Confidence Interval: 0.371-1.485).
Conclusions. Examination of the relative roles of pain and opioid administration on the
development of delirium experienced by this population provides evidence that opioids
predict the onset of next-day delirium, which has implications for the use of these
commonly administered mediations to older adults in the SICU setting. In an effort to
prevent delirium, future research should focus on both pharmacological and nonpharmacological opioid-sparing pain management approaches.
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Introduction
Delirium is believed to occur in approximately 50% of all older hospitalized adults.1 It is
defined as an acute change in cognition and attention not described by a pre-existing
condition, established or evolving dementia.2 Delirium is a known risk factor for poor
outcomes in patients admitted to the surgical intensive care unit (SICU),3-6 and is
associated with longer hospital and intensive care unit (ICU) length of stay, 7 persistent
functional decline6,8-13 and mortality.3,14-17 Recent studies have shown that outcomes
worsen as the duration of delirium increases.9,18,19 Further, delirium significantly
increases health care costs, ranging from an additional $16,303 to $64,421 per patient.20
To date, no single pharmacological intervention has been shown to be effective in
treating delirium.6 Multiple variables are believed to contribute to the development of
delirium, including underlying health conditions, inflammatory processes,
neurotransmitter disruptions, physiological stressors, and metabolic derangements,6,21-24
however the pathophysiology of delirium remains poorly understood. While numerous
risk factors for delirium have been identified,17,25-28 many are non-modifiable, such as
admission to the ICU, duration of illness, and increased age. 25-27 Current interventions
for the prevention of delirium include ensuring pain, a modifiable risk factor, is
adequately managed while minimizing the use of medications to treat pain, such as
opioids.28,29 The finding that both pain, and its management, can contribute to the onset
of delirium suggests that their relative roles in improving delirium outcomes warrant
further investigation.
Pain is a potent and common stressor present in approximately 80% of critically ill
patients admitted in the SICU,30 and is commonly identified as a precipitating factor for
the development of delirium.31-34 However, there is surprisingly limited evidence to
support a causal association between untreated pain and the development of delirium.
Several older studies have examined how the presence of postoperative pain may
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contribute to the occurrence of delirium, however the findings are mixed.31-34 Because
the relationship between pain and delirium is not well-established, it is unclear that the
pharmacological management of pain will prevent delirium in critically ill patients.
Medications are thought to account for 12% to 39% of all cases of delirium.25
Specifically, results from systematic reviews show that opioid analgesics,28,29
hypnotics,35-38 benzodiazepines,37,39 anticholinergic agents,25,32 antihistamines,25 and
corticosteroids7,25 are each associated with the development of delirium. Opioids are the
most common analgesics administered to patients following surgery, and morphine,
fentanyl, and hydromorphone are those most frequently used.28,29 An association has
been reported between opioid use and the development of delirium in patients admitted
to an ICU26 and with the use of opioids in general across hospital settings.25 However,
these studies have limited generalizability and are graded of low to moderate quality
evidence.25,26,28
The aim of this investigation was to evaluate the relationships among acute
postoperative pain severity, opioid analgesic administration and the onset of delirium
among older adults in the SICU. As outlined in the conceptual framework (see Figure
4.1), it is hypothesized that pain severity and opioid use are each positively correlated
with the onset of delirium, and that opioid administration will decrease pain. These
analyses enable comparison of the relative and combined roles of pain severity and
opioid administration on delirium onset, providing direction for the management of these
delirium risk factors.
Methods
Study Design
Utilizing a longitudinal study design, data were collected from a single hospital SICU to
examine the relationships among the onset of delirium, pain severity, and opioid
analgesic administration in older adult patients aged 65 years or older. The observation
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period was from March 15, 2018 to August 15, 2018. Daily average pain scores, daily
worst pain scores, and daily opioid medication exposure were calculated from the time of
ICU admission until discharge or up to 7 days and inspected to see how these predicted
next-day delirium. Based on other reports in the literature, the sampling period was
limited to 7 days as patients whose delirium emerges beyond 7 days may be suffering
from an underlying medical abnormality or complications that are not representative of
SICU delirium.26,40
All data were extracted from the electronic health record (EHR). The University of
Pennsylvania Institutional Review Board approved this exempt research project and
granted a waiver of informed consent prior to its initiation. Study design and reporting
criteria outlined in the STrenghtening the Reporting of OBservational studies in
Epidemiology (STROBE) were followed.41
Sample and Setting
Study participants were selected from a 24-bed SICU at the Hospital of the University of
Pennsylvania, which is a 795-bed, urban academic teaching hospital. Inclusion criteria
were; age  65, English speaking, admitted to the SICU for >24 hours, and screened for
delirium using the confusion assessment method for the intensive care unit (CAM-ICU)
anytime between day 1 and day 7 during their admission to the SICU. Patients were
excluded if they had an admitting diagnosis related to neurological or central nervous
system injury; for patients readmitted to the SICU, only the index admission was
evaluated.
Measures
Delirium. Delirium was identified using the highly reliable and well-validated CAM-ICU
tool.42-44 Delirium was defined as one positive CAM-ICU screening in a 24-hour period
calculated beginning at the time of ICU admission through ICU discharge or up to 7
days. Delirium onset was defined as being free of delirium in the preceding 24-hours.
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The CAM-ICU assessment was completed by trained nurses every 12 hours and
recorded in the EHR.
Pain. The nursing staff completed pain assessments every 4 hours beginning on
admission to the SICU. Pain severity was measured using a self-reported 10-point
numeric rating scale, where 0 indicates no pain and 10 indicates worst pain ever. Pain
scores were extracted from the EHR and averaged for each 24-hour period during days
1-7, providing an average daily pain score; in addition, the highest (worst) pain score
recorded each day was extracted for analysis.
Opioid Exposure. Daily opioid use was also extracted from the EHR for analysis. The
opioids to which patients were exposed included; acetaminophen-codeine #3, fentanyl,
hydromorphone, methadone, morphine, oxycodone, oxycodone-acetaminophen and
tramadol. Routes of administration varied by medication and comprised oral,
intravenous, epidural and patient controlled analgesia. Exposure was defined as any one
instance of opioid administration (any type or route) during a 24-hour period.
In addition, patient characteristics including age, sex, weight, race and admitting
diagnosis were extracted from the EHR to describe the population of interest. Use of
mechanical ventilation, Richmond Agitation-Sedation Scale (RASS) scores and sedative
medications (benzodiazepines and propofol) were also examined as potential
covariates.
Statistical Methods
To compare patients who developed delirium with those who did not, student’s t-tests for
independent groups were used to assess continuous variables and chi-square (𝜒2) tests
were used to assess categorical variables. P-values of 0.05 or less were considered to
indicate statistical significance. Data were closely examined for any systematic patterns
of missingness. Pain severity (24-hour average, daily worst) and opioid exposure were
assessed as predictors of next-day delirium status using generalized estimating equation
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models. The generalized estimating equations method was applied using the Genmod
procedure in SAS, which is able to account for correlation within subjects’ repeated
observations and allows for the assessment of time varying exposure covariates. Daily
pain (24-hour average) and opioid exposure were assessed together as predictors of
next-day delirium status in a multivariable general estimating equation model. Lastly,
daily pain (24-hour average), opioid exposure, propofol exposure, mechanical ventilation
and RASS were assessed together as predictors of next-day delirium status in a
multivariable general estimating equation model.
Results
The final sample was comprised of 172 patients, 56 of whom experienced delirium
during the SICU stay and 116 who did not. Demographically, the two cohorts were
comparable (Table 4.1) and there were no differences in admitting diagnosis. As noted,
both pain (24-hour average) and worst pain scores, averaged across Days 1 to 6, were
slightly more severe for patients who did not develop delirium, although not to a
statistically significant degree. Delirium was significantly associated with a higher
number of days exposed to opioids (P = .0018) and propofol (P < .001) in comparison to
patients who did not develop delirium, however not associated with a number of days
exposed to benzodiazepines (P = .1253). In addition, patients who developed delirium
received mechanical ventilation (P < .001) and for a greater number of hours (P < .001).
When assessed using generalized estimating equation models, neither average pain
score (𝜒2, 1.02, P = .3135) nor worst pain score (𝜒2, 0.93, P = .3353) were found to be
significantly associated with next-day delirium onset (Table 4.2). There was however, a
statistically significant association between opioid exposure and next-day delirium status
(𝜒2, 11.53, P = .0007). Specifically, the odds of next-day delirium for a patient treated
with opioids were 2.2 times those of a patient not treated with opioids (95% Confidence
Interval [CI]: 1.300-3.638). In that propofol was found to be significantly associated with
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delirium in the initial descriptive analysis, it was assessed as a predictor of next-day
delirium in a generalized estimating equation model. Propofol exhibited a statistically
significant association with next-day delirium status (𝜒2, 10.29, P = .0013), and the odds
of next-day delirium for a patient receiving propofol were 2.7 times those of patients who
were not exposed to propofol (CI: 1.457-4.916).
Daily pain severity (average) and opioid exposure were assessed together as
predictors of next-day delirium status in a multivariable general estimating equation
model (Table 4.3). Again, opioids (𝜒2, 12.60, P = .0004), but not pain (𝜒2, 3.61, P =
.0573) were statistically significant in predicting next-day delirium status. When
controlling for pain severity, patients exposed to opioids exhibited odds of next-day
delirium that were 2.5 times those of patients not exposed to opioids (CI: 0.371-1.485).
Because propofol exposure was a strong predictor of next day delirium in the
descriptive analysis, it plus the indications of propofol administration (mechanical
ventilation, RASS score), were assessed with daily pain severity (average) and opioid
exposure as predictors of next-day delirium status in a multivariable general estimating
equation model. Opioids (𝜒2, 5.02, P = .0251) remained statistically significant in
predicting next-day delirium status; however pain (𝜒2, 0.99, P = .3189), propofol
exposure (𝜒2, 2.75, P = .0974), use of mechanical ventilation (𝜒2, 1.86, P = .1723) and
RASS (𝜒2, 1.82, P = .1771) were not statistically significant in predicting next-day
delirium status (Table 4.4). In the multivariable model, the odds of next-day delirium for
a patient exposed to opioids were 1.9 (CI: 1.0042 – 3.4925) and for patients exposed to
propofol 1.9 (CI: 0.9568 – 3.7922) times those of a patient not exposed to either drug
respectively.
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Discussion
Both untreated pain and opioid analgesics have been implicated in the development of
delirium in older adults in the intensive care unit setting.31,32,34,45 Our analyses evaluated
the relative role of these risk factors in predicting delirium onset in a well-characterized
sample of older adult patients in the SICU. The results indicate that medications play a
greater role in delirium development than pain and suggest that medication
administration may be a modifiable risk factor to mitigate its occurrence.
Pain regularly occurs in adult ICU patients and can impede patients from actively
participating in their care (e.g., early mobilization, participation in spontaneous breathing
trials, weaning from mechanical ventilation).45 The stress response produced by acute
pain can lead to negative, both short- and long-term consequences for adults in the ICU.
Specifically, acute pain is a risk factor for developing chronic, persistent, often
neuropathic pain.46 Untreated pain is an oft-cited precipitating factor of delirium; in fact,
The Society for Critical Care Medicine identifies pain as a modifiable risk factor for the
development of delirium.45 Nevertheless, empirical evidence supporting its relationship
on the development of delirium is surprisingly limited32,34,47 and few studies have
examined how the presence of pain contributes to the occurrence of delirium in the SICU
population specifically.34
A study of 361 patients undergoing major elective noncardiac surgery evaluated pain
at rest, pain with movement, and maximum pain. The authors found that in when
stratified by surgical procedure, patients with higher pain scores at rest were at
increased risk of developing delirium of the three postoperative days studied (risk ratio
1.2, P = 0.015).32 Similarly, Vaurio and colleagues studied 333 older adults scheduled for
non-cardiac surgery concluded that severe pain (OR, 3.7; 95% CI 1.5 to 9.0) was
independently associated with the development of delirium.34 Newer evidence has not
sufficiently drawn definitive conclusions between the relationship of pain and delirium,
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which may be related to the practice of aggressively treating pain in the acute care
setting.
Our results demonstrated that average and worst pain score were not predictive of
next-day delirium status. As noted, weekly averaged pain scores were in the low to
moderate range. Although insignificant, patients with delirium had lower pain severity
ratings than those patients without delirium, suggesting that opioid provision, although
deliriogenic, was also an effective analgesic. The results of this investigation provide
additional support that while unrelieved pain may lead to its own detrimental
consequences, it may not be predictive of the development of delirium and suggest that
pain management with opioids may be responsible for confounding this relationship.
Consistent with the results of a systematic review,25 opioids were a strong predictor
of delirium onset, more than doubling the odds of delirium developing the day following
opioid administration (APPENDIX C). After evaluating the literature, two studies have
indicated protective effects of opioids reporting reduced rates of delirium, 48,49 four studies
show no association between opioids and delirium status, 50-53 and seven studies
attributed opioid use to the development of delirium.25,26,47,54-57 Our results will add to this
growing body of literature implicating opioid use as a risk factor for delirium.
Opioids have known psychoactive and depressant effects on cortical function,
resulting in diminished cognitive performance, which has been implicated in the decline
in cognitive function hallmark of delirium.58 Opioid-induced delirium is thought to be the
result of underactivity of the cholinergic system.1,59 In the central nervous system,
cholinergic projections from the basal forebrain to the thalamus and cortex are critical in
supporting key cognitive functions, such as maintaining alertness, sustaining attention,
and learning and memory.60-62 Opioids appear to impair cognitive processing, leading to
the development of delirium, due to obstruction of this vital cholinergic transmission.63,64
Inhibition of acetylcholine from morphine has also been implicated in decreasing rapid
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eye movement (REM) sleep and disrupt sleep architecture.65 These perturbations in
sleep architecture may then, in turn, affect arousal and lead to impaired attention, which
are early indicators of the development of delirium.66
Disruption of the cholinergic system has also been associated with the memory
deficits in Alzheimer's disease. A substantial proportion of patients who survive delirium
are likely to experience long-term cognitive impairment similar to mild Alzheimer’s
disease6,8-13 for up to one year post-discharge.19 A recent study placed the odds of
requiring of institutional care post-hospitalization at rates 2.4 times higher in patients
who suffer from delirium than those who did not,17 suggesting that opioid exposure in the
SICU may not only be associated with delirium onset, but also post-delirium memory
deficits. The results of this study add to the growing body of literature reporting an
association between opioid use and the development of delirium in patients admitted to
an ICU25,26,67 and with the use of opioids in general across hospital settings.25
Historically, benzodiazepines (i.e., midazolam and lorazepam) and propofol have
routinely been used to provide sedation in the ICU. Older guidelines recommended
midazolam for short-term sedation, lorazepam for long-term sedation, and propofol for
patients requiring occasional awakenings.68 As an emphasis on delirium-related patient
centered outcomes have become more prevalent, trials began implicating
benzodiazepines as a likely culprit for delirium.37,39,69 While this association was not
noted in our sample, exposure to benzodiazepine was limited and under-powered to
capture this effect (post-hoc power analysis, 33% power to detect statistical significance
at the alpha = 0.05 level). Low rates of exposure to benzodiazepines in this sample likely
reflect benzodiazepine-sparing practices in the SICU to avoid deliriogenic effects.
The 2018 Society of Critical Care Medicine guidelines now recommend propofol,
over benzodiazepines, as first-line sedation for most patients in the ICU.45,70
Interestingly, while significantly associated with delirium alone, after controlling for
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mechanical ventilation and RASS as covariates, the deliriogenic effect of propofol on
next day delirium was weakened. Propofol is routinely used due to its quick onset, short
duration of action, and relatively low cost.38,63 While exposure to propofol has the
potential for sedative and psychoactive effects such as impaired memory and delayed
motor performance,71 the mechanism by which it causes delirium is unclear. A review
article by Brown and colleagues cite evidence from in vitro studies suggesting that
propofol may interact with acetylcholine receptors.72 Similar to opioids, this cholinergic
deficit may also be responsible for propofol delirium-inducing side effects.
Our finding that propofol exposure was associated with next-day delirium status,
support and extend those of other studies that have examined the association between
propofol and delirium. The association between delirium and propofol use has been
evaluated in 15 studies; three descriptive and 12 comparison studies (APPENDIX D).
Two out of three descriptive studies73-75 correlated propofol administration with increased
rates of delirium. In a study of 149 patients admitted to the ICU, 69 developed delirium
(46.3%) and propofol was administered to 23 patients (33.3%) of these patients,
compared to just 6 patients (7.5%) without delirium (P < .001).74 In a sample of 115
patients, Bryczkowski and colleagues, reported higher average cumulative doses of
propofol in patients with delirium (6 mg/kg/d vs. 1 mg/kg/d; P < .001).75 Finally, a study of
451 patients undergoing spinal surgery found that 42 patients (9.3%) developed
delirium, and there was no appreciable difference in the use of propofol between those
who developed delirium and those who did not.73
As the hallmark of routine sedation, propofol is often used as an active comparator in
clinical trials evaluating alternative medications for the reduction of delirium outcomes in
the ICU. When used as a comparator in clinical trials, some, but not all studies confirm
that propofol results in worse delirium-related outcomes. Comparators included one
study of opioids, one study of benzodiazepines and ten studies utilizing
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dexmedetomidine. A retrospective study of 100 patients compared fentanyl sedation (n =
50) versus traditional sedation with propofol (n = 50) found no difference in the
development of delirium between groups (P = .80).53 In a sample of 140 patients
admitted to the ICU receiving propofol or benzodiazepines for sedation, higher daytime
administration of propofol was marginally (P = .60) associated with next-day delirium
onset.76 Of the ten studies evaluating propofol versus dexmedetomidine for the
reduction of delirium, no study reported propofol superior to dexmedetomidine for the
reduction or prevention of delirium. Four studies reported superiority with
dexmedetomidine,35,36,77,78 and six studies showed no difference in the incidence of
delirium between groups.38,79-83 Ultimately, more studies are needed to understand the
role of propofol as a precipitating factor in the development of delirium. The results of
this investigation add to the growing body of literature, suggesting that even a single
exposure to propofol may increase the likelihood for developing delirium in the SICU.
Sedatives, like propofol and benzodiazepines, are regularly used in the ICU to
mitigate the agitation associated with mechanical ventilation. Recent literature indicates
that both maintaining a deep level of sedation (measured by RASS) and longer duration
of mechanical ventilation are associated with the development of delirium, increased ICU
length of stay, and acquired weakness due to immobility.84 Because propofol exposure
was significant in the exploratory analysis, RASS and use of mechanical ventilation were
added as covariates to the final model to test their association with the onset of next day
delirium status. Notably, patients with delirium spent approximately 66 hours (median)
on mechanical ventilation compared to just 18 hours in patients without delirium. In the
multivariable analysis, mechanical ventilation did not increase the odds of next day
delirium, suggesting that the medication administered to manage mechanical ventilation
(propofol), not the ventilation itself, was associated with the development of next-day
delirium. Importantly, RASS between the two groups was similar with average scores in
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range of light sedation (RASS = 0, -1), and was not significantly associated with the
development of next day delirium. These analyses enabled comparison of the relative
and combined roles of pain severity, opioid and propofol exposure, mechanical
ventilation and RASS on the onset of delirium, providing direction for management of
these modifiable delirium risk factors.
The role of opioids and propofol in the development of delirium may be due to
interruptions of the natural sleep-wake cycles.6,66,70,85 Recent evidence supports the
promotion of sleep, aiming to provide at least 4 hours of sleep per night, for the reduction
of delirium.86 One study has reported that delirium was associated with greater circadian
sleep-cycle disruption and increased daytime sleep. 85 The Society of Critical Care
Medicine updated their Pain, Agitation and Delirium (PAD) guidelines were recently
updated to now include Immobility (rehabilitation/mobilization), and Sleep (disruption)
(PADIS). Importantly, only two of the 37 recommendations are graded as strong; most
are conditional (the evidence is conflicting, low quality, insufficient). The specific
recommendations related to sleep are conditional, with low to very low evidence. The
committee hopes that by adding sleep to the guidelines it will encourage the completion
of pragmatic, patient-centered research to answer these important critical care demands.
Limitations
There are several important limitations of this study. Due to limitations in the dataset,
only dichotomous medication exposures (opioid, propofol, benzodiazepines) were
evaluated. Therefore, potential effects of dose or route of administration were unable to
be derived. In addition, no medication exposure or pain score information was available
prior to arrival in the ICU, so their predictive role for day 1 delirium status was unable to
be evaluated. Also, as noted, aggressive pain management and low rates of
benzodiazepine use in the SICU may have precluded a true assessment of the effects of
each on delirium onset.
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The approach and findings are limited to the data collected during the defined study
period. Due to lack of randomization to medication exposure or pain levels, selection
bias is a potential threat to the internal validity of the study, and it is possible the
observed changes may not be attributed to the medication exposure. It is also possible
that the patient populations and baseline processes of care for delirium management at
HUP may not be generalizable to other hospitals and health systems.
Future Directions
Literature that specifically addresses the relationships among delirium, pain severity and
analgesia and sedation management for older adults admitted to the SICU is growing. In
that opioid exposure was the strongest predictor of delirium onset in this study, opioidsparing approaches may be the best intervention to prevent its development. Pragmatic
clinical trials are needed to prospectively evaluate if reduction in opioid administration,
and pain control with non-opioid pharmacologic strategies are successful in reducing the
onset of delirium. As health care systems respond to the opioid epidemic, opioid-sparing
strategies for pain management in acute care settings are encouraged.87 Therefore,
other types of analgesics and non-pharmacologic pain management approaches may be
considered as covariates in future analyses.
Contemporary guidelines, such as ICU Liberation, encourage lighter sedation targets
to minimize the negative consequences of deep sedation,45,70 and consequently, may
reduce exposure to propofol. A number of alternative pharmacological strategies to both
prevent and treat delirium have been, and continue to be, highly tested including,
antipsychotic medications,54 acetylcholinesterase inhibitors,88 melatonin,89 and
gabapentin.88 Studies purport that dexmedetomidine may reduce or prevent
delirium,6,22,24,66,77,90-93 and recent studies of intravenous acetaminophen are receiving
praise as a possible alternative to opioids due to the analgesic and inflammatory

100

properties of the drug.83 Thus far, no single strategy has amassed enough evidence to
support its role in delirium prevention or treatment.
Conclusions
This study is among the few to characterize the relative relationships among pain, opioid
analgesia and sedation with propofol in the onset of delirium in older adults admitted to
the SICU. Pain was not found to be a contributor to next-day delirium status however,
both opioid and propofol exposure were strong predictors of delirium onset in this
sample. Future research should focus on medication-sparing approaches to manage
pain and achieve sedation as a means to prevent delirium.
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Figures and Tables

Figure 4.1 Conceptual Model of the Effects of Pain and Opioid Analgesia on
Delirium
This conceptual framework postulates that pain severity and opioid use are each
positively correlated with the onset of delirium, and that opioid administration will
decrease pain.
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Table 4.1 Characteristics of Sample
Characteristics
Number of Patients

No Delirium
116

Delirium
56

p-value
0.464

Age (years), median (range)

72 (65, 92)

73 (65, 88)

0.6249

Sex (male), n (%)

75 (65%)

33 (59%)

0.467

Weight (kg), median (range)

80 (45, 133)

81 (44, 172)

0.9980

Race
Asian
Black or African American
Hispanic
Unknown
White
Other

1
9
1
15
90
0

0
7
0
6
42
1

Medication Exposures, mean days ± sd
Opioids
Propofol
Benzodiazepines

1.2 ± 1.7
0.2 ± 0.7
0.2 ± 0.7

2.0 ± 2.2
1.1 ± 1.6
0.4 ± 1.0

<0.0018*
<0.001*
0.1253

Pain Scores (0-10) Days 1 to 6, median (range)
Average
Worst
Mechanical Ventilation %
median hours (range)
RASS median (range)

3.7 (0, 8.7)
4.2 (0, 9.8)
29 (25%)
18 (1-168)
0 (-4 to 0)

2.7 (0. 8.2)
3.5 (0, 9.3)
40 (71%)
66 (9 -168)
-1 (-2 to 0)

0.2453
0.1936
<0.001*
<0.001*
0.39

0.530

Admitting Diagnosis (ICD-10-CM Codes)
A00-B99 Infectious and parasitic diseases
C00-D49 Neoplasms
E00-E89 Endocrine, nutritional and metabolic
disease
H60-H95 Diseases of ear and mastoid process
I00-I99 Diseases of circulatory system
J00-J99 Diseases of respiratory system
K00-K95 Diseases of digestive system
M00-M99 Diseases of musculoskeletal system
N00-N99 Diseases of genitourinary system
R00-R99 Symptoms, signs & abnormal labs
S00-T88 Injury, poisoning & other external causes
Z00-Z99 Factors of health status & contact health
services

0.365
2
27
1

5
9
0

0.26
0.265
1.0

1
16
3
27
1
4
25
6
2

0
11
0
14
2
1
11
3
0

1.0
0.335
0.552
0.827
0.250
1.0
0.752
0.969
1.0

*indicates statistical significance.
Abbreviations: (kg) kilogram; (sd) standard deviation; (ICD-10-CM) International Classification of Diseases, Tenth
Revision, Clinical Modification.
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Table 4.2 Odds of Pain and Medication Predicting Next-Day Delirium
chi-square p-value Odds Ratio 95% Confidence Interval
Pain Score - Average
1.02
0.3135
0.95
0.86 - 1.05
Pain Score - Worst
0.92
0.3353
0.96
0.88 - 1.05
Opioid Exposure
11.53
0.0007*
2.2
1.30 - 3.64
Propofol Exposure
10.29
0.0013*
2.7
1.5 - 4.92
*indicates statistical significance

Table 4.3 Predictors of Next-Day Delirium
chi-square p-value Odds Ratio
Pain Score - Average
3.61
0.0573
0.90
Opioid Exposure
12.60
0.0004*
2.50

95% Confidence Interval
0.81 – 1.00
1.45 - 4.42

*indicates statistical significance

Table 4.4 Multivariate Predictors of Next-Day Delirium
chi-square p-value Odds Ratio
Pain Score - Average
0.99
0.3189
0.95
Opioid Exposure
5.02
0.0251*
1.9
Propofol Exposure
2.75
0.0974
1.9
Mechanical Ventilation
1.86
0.1723
0.43
RASS
1.82
0.1771
0.58

95% Confidence Interval
0.84 – 1.06
1.0042 – 3.49
0.96 – 3.79
0.14 - 1.31
0.27 - 1.26

*indicates statistical significance
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Chapter 5
Discussion
Delirium affects more than 2.6 million older adults admitted to the intensive care unit
(ICU) each year and can be a life-threatening.1 Nurses are uniquely prepared to drive
solutions to address this clinically significant problem by recognizing risk factors and
initiating evidence-based nursing interventions. The Hospital of the University of
Pennsylvania created the ICU Liberation Executing the ABCDEF Bundle Daily (iLEAD)
protocol to implement the ABCDEF bundle and reduce the consequences of delirium in
the ICU. The overall objectives of this research were to describe the effectiveness of
the iLEAD intervention to reduce the burden of delirium and its associated adverse
outcomes, and to examine the relative roles of two modifiable risk factors associated
with delirium (pain, opioid administration).
Chapter 2 of this proposal served as the groundwork for the research aims and
hypotheses by providing an increased understanding of the most current treatment
strategies, delirium research methods, and the issues associated with identifying and
managing delirium. Appreciative of deficits in delirium identification and management,
Chapter 3 evaluated the efficacy of a new nurse-led preemptive identification, treatment
and management strategy (iLEAD) to improve delirium-related patient and clinical
outcomes (days of delirium, length of stay, readmissions and mortality). Lastly, Chapter
4 continued investigation into the link between pain, opioid pain management, and the
onset of delirium. Overall, this dissertation research has important implications in moving
forward nurse-driven approaches to the clinical care of older adults in critical care
environments at risk for experiencing delirium.
This dissertation research contributes to the existing knowledge that delirium is
detrimental to the health of older adults. Importantly, the work brings attention to
proposed risk factors for delirium in surgical intensive care patients, pain, and its
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treatment with opioids. Continued investigation into the relative roles of pain and pain
management on the onset of delirium will be invaluable for future delirium research and
is vital to improve patient outcomes in older adults.
Major Findings from Chapter 2
There is inadequate, conclusive, evidence supporting pharmacologic interventions for
the treatment or prevention of delirium. This integrative review of 16 peer-reviewed
publications examined the efficacy of the novel alpha-2 agonist, dexmedetomidine in
lowering the incidence of delirium compared to other analgesic and sedation strategies.
The results of this analysis suggest that dexmedetomidine administration does not
reduce the incidence and/or duration of delirium uniformly across all patient populations
studied. However, there was good evidence to support postoperative administration of
dexmedetomidine reduces delirium in patients, particularly following cardiac surgical
procedures, supporting the results of recent meta-analysis.2 Further research is needed
to determine the benefits of dexmedetomidine in patients on mechanical ventilation and
optimal timing and duration of administration.
As with much of the research in this field, the focus was on evaluating pharmacologic
strategies to treat delirium. In future work, non-pharmacologic delirium interventions,
pain management, and quality of sleep need to be included in these validation studies.
Importantly missing from this literature is the effect of independent nursing interventions
on delirium outcomes. Each of these dimensions (pain management, sleep, and
medication administration) are areas in which nurses are important stakeholders and
should help drive this research forward. As the population continues to age and the
incidence of comorbid illnesses grows, addressing the prevention and reduction of
delirium is a timely and imperative objective. The results of this integrative review were
vital for elucidating the insufficiencies in delirium identification and management
addressed in Chapters 3 and 4.
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Major Findings from Chapter 3
The iLEAD is a nurse-driven protocol aimed at reducing the severity of delirium in the
intensive care unit via the implementation of independent nursing interventions. When
nurses routinely assess and manage modifiable risk factors for delirium, it was
hypothesized that the number of days of delirium would decrease and patient outcomes
would improve. Specifically, this retrospective study evaluated the impact of the iLEAD
intervention on the number of days with delirium, length of stay in the SICU, overall
hospital length of stay, 30-day readmission rates and 30-day mortality experienced by
older adults in the SICU with delirium.
Following iLEAD, implementation rates of delirium screening more than doubled,
reflecting that nursing staff were highly motivated to address this critical issue facing
patients in the SICU. Consistent with previous reports, patients with delirium in this study
had increased SICU and overall hospital length of stay, and higher 30-day mortality rates
when compared to patients without delirium. Other than a trend for improvements in
rates of 30-day readmissions, no statistically significant improvements in delirium
outcomes were noted for the patients who received iLEAD delirium-informed care.
However, benefits associated with the iLEAD intervention may not have been detected
because previously undiagnosed incidents of delirium (pre-implementation) were now
identified (post-implementation), increasing measurement of the overall negative
outcomes. Despite the lack of statistical significance, the clinical implications remain
significant. Reducing delirium-related consequences even by one day may have
substantial significance for patients, both in terms of health outcomes and healthcare
related costs. As the iLEAD intervention continues to be implemented, patient-centered
outcomes may show additional improvement. Delirium continues to be a noteworthy
threat to the health of older adults, and dedicated nurse stakeholders are essential in
advancing research.
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Major Findings from Chapter 4
This cross-sectional secondary analysis study of older adult patients admitted to the
SICU evaluated the relationships among pain severity, its management with opioids, and
the onset of delirium. Examination of the relative roles of pain and opioid administration
on the development of delirium experienced by this population are important contributors
to evidence-based guidelines on pain management. Developing approaches that
maximize pain relief while minimizing the negative outcomes related to delirium are
essential. The results of this investigation show that opioid exposure was the greatest
predictor of next-day delirium status, followed by propofol administration. Interestingly,
neither daily average nor worst pain score were associated with next day delirium.
As the most commonly administered medications to patients in the SICU, the roles of
opioids and propofol in delirium onset requires further explication. Medications are
thought to account for 12% to 39% of all cases of delirium.3 The results of this
investigation provide additional support that while untreated pain may have detrimental
consequences, it may not be predictive of the development of delirium. In the literature,
the language surrounding pain and delirium suggests causation, however this may be
inappropriate given the potential for the confounding of observational data in a syndrome
with intersecting, poorly understood, and underlying pathologic mechanisms. This
observational research study cannot demonstrate causality but offers additional
description of the relationship between pain and delirium. Too many studies have
posited the causal link between pain and delirium with too few studies actually
supporting this relationship, and more rigorous evidence is profoundly lacking.
Limitations
It is important to recognize several limitations of this research. First, patients were not
randomized to receive the iLEAD intervention. Therefore, selection bias is a possible
threat to the internal validity of this study. Second, data collection was limited to the
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electronic health record, and inconsistencies in the accuracy and documentation of the
assessments performed is another potential limitation to interpretation. Any conclusions
drawn by this study regarding the contributions of the specific nursing’s interventions
implemented will require prospective validation in future studies.
Lastly, due to the retrospective observational nature of these analyses, the ability to
demonstrate causation is not possible. It does, however, afford an important opportunity
to examine the association between routine screening and patient outcomes for delirium,
along with the associations among pain, its management with opioids, sedation and
delirium onset. These investigations represent the first studies to evaluate the iLEAD
intervention, originally designed as a health systems science initiative. Therefore, this
observational approach took advantage of the natural experimental nature of this
protocol implementation in effort to provide health systems and organization-level
feedback. As such, the outcomes may not be immediately exportable to other health
systems. It is also possible that the patient populations and baseline processes of care
for delirium management may not be generalizable to other hospitals and health
systems.
Implications
Importantly, this investigation is the first evaluation to determine the impact of iLEAD
bundled independent nursing interventions to treat the significant and costly problem of
ICU delirium. Nurses’ clinical expertise and front-line responsibilities make them uniquely
qualified to champion these efforts. The implications of this health systems science
dissertation research demonstrate that nurse-led interventions for the reduction and
prevention of delirium are feasible, and potentially, as time goes on, may be effective.
Close examination of the literature reveals that there is little empirical evidence to
support the causal relationship between pain and the development of delirium. Pain
severity was not predictive of delirium in this sample, however exposure to the class of
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analgesic most commonly used to treat pain, the opioids, made the patient twice as
likely to result in next-day delirium. This suggests that opioids, administered to counter
pain, contribute to delirium development. The role of pain management with opioids in
the development of delirium requires explication. This study is among the few to
characterize the relative roles of pain and opioid administration on the onset of delirium
in the surgical ICU population.
Sedatives, like propofol and benzodiazepines, are regularly used in the ICU to
mitigate the agitation associated with mechanical ventilation. While significantly
associated with delirium alone, after controlling for mechanical ventilation and RASS as
covariates, the deliriogenic effect of propofol on next day delirium was weakened. The
use of mechanical ventilation varied greatly in the sample however, it did not increase
the odds of next day delirium, suggesting that propofol administration, not the ventilation
itself, was associated with the development of next-day delirium. These analyses
enabled comparison of the relative and combined roles of pain severity, opioid and
propofol exposure, mechanical ventilation and RASS on the onset of delirium, providing
direction for management of these modifiable delirium risk factors.
In summary, this research evaluated the effectiveness of the nurse-led iLEAD
intervention to reduce the burden of delirium and its associated adverse outcomes.
Further, it examined two modifiable risk factors associated with delirium (pain, opioid
administration). Overall, this dissertation research has important implications in moving
forward nurse-driven approaches to the clinical care of aging adults in critical care
environments at risk for experiencing delirium.
Future Directions
The older adult population is at the greatest risk for developing ICU delirium, and, at
present, there is no consensus on best strategies for its prevention or management.
Most studies focus on pharmacologic strategies to reduce delirium, while far fewer have
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included reports of non-pharmacological interventions (see Table 1.1) as part of their
reduction strategies. The lack of this information makes it difficult to assess if these nonpharmacologic strategies, incorporated in many ICUs, play a role in the reduction of
delirium. Despite limited evidence, use of such supportive measures has nevertheless
become standard practice on the basis on clinical experience and lack of adverse
effects. Formally evaluating these non-pharmacologic strategies represents a rich
opportunity for future research.
In addition, there is significant knowledge to be gained from the Hospital Elder Life
Program (HELP), designed by Dr. Sharon Inouye and colleagues. HELP is an evidencebased, patient-care program to maximize independence for older adults posthospitalization.4 The HELP program focuses on consistently reorienting patients to their
surroundings, ensuing nutritional goals are meet, prioritizing sleep-promoting
interventions while encouraging mobility during hospitalization. Rates of delirium in
elderly patients have been significantly improved following the HELP program. With
more than 200 HELP sites, the program has been successful in returning older adults to
their homes (or prior living situations) with preserved or improved cognitive and physical
function. A community hospital employing the HELP program evaluated 595 patients 70
years of age or older admitted to a general medicine floor, and reported a 40% reduction
in delirium incidence resulting in a cost savings of $841,000 over 9 months. 5 The HELP
program relies on the support of highly trained and supervised volunteers to enable oneto-one support and delivery of personalized interventions to achieve optimal outcomes.
While many large-scale health systems may find it difficult to achieve this level of
personalized care, the associated cost savings may provide financial incentive to
incorporate these strategies.
The short-term consequences of pharmacologic pain management strategies may
contribute to the development of delirium. Pragmatic clinical trials are needed to
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prospectively evaluate if reduction in opioid administration, and pain control with nonopioid pharmacologic strategies, are successful in reducing the onset of delirium. A
number of alternative pharmacological strategies to both prevent and treat delirium have
been, and continue to be, highly tested. Thus far, no single strategy has amassed
enough evidence to support its role in delirium prevention or treatment. While
dexmedetomidine has shown promise, additional studies are needed.
A possible explication for the role of opioids and propofol in the development of
delirium may be due to interruptions of the natural sleep-wake cycles. Recent evidence
supports the promotion of sleep, aiming to provide at least 4 hours of sleep per night, for
the reduction of delirium.6 Dexmedetomidine is an attractive choice for delirium therapy
or prevention, as it is believed to mimic natural sleep architecture and reduce pain. If
sleep is a potential curative or preventative measure for reducing the incidence of
delirium, nighttime administration of dexmedetomidine may be advantageous in aligning
patients with their natural circadian rhythms to facilitate more restful and restorative
sleep. Validation studies are needed to evaluate day-time versus nighttime drug
administration. In addition, metrics of quality of sleep should be included in other
prospective evaluations of delirium, including those using opioids and propofol as active
comparators.
Conclusions
In conclusion, this dissertation research contributes to the current understanding of the
consequences of delirium among older adults in the surgical intensive care unit. This
work described the effectiveness of the nurse-led iLEAD intervention to reduce the
burden of delirium and examined two modifiable risk factors associated with delirium
(pain, opioid administration). This dissertation research expands knowledge of deliriumrelated patient and clinical outcomes (days of delirium, SICU length of stay, hospital
length of stay, 30-day readmissions and 30-day mortality) and facilitates continued
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investigation into the link between pain, opioid analgesics and the onset of delirium.
Overall, this dissertation research has important implications in moving forward nursedriven approaches to the clinical care of aging adults in critical care environments at risk
for experiencing delirium.
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APPENDIX A
iLEAD

Protocol
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APPENDIX B
Study Variables and Operational Definitions
Type
Independent

Variable
iLEAD
(Specific Aim 2)

Definition
A nurse-led intervention assessing and
managing risk factors for delirium.

Measured by
Time period

Units/Range/Frequency
Pre vs. Post

Data Type
Dichotomous

Independent

Pain scores
(Specific Aim 3)

A measure a patient's pain intensity.

Numeric Pain
Scale

0 - 10
Every 4 hours

Numeric continuous, ratio

Independent

Opioid exposure
(Specific Aim 3)

Opioids administered to treat pain.

Exposure

Yes/No

Dichotomous

Dependent

Days of Delirium

A positive CAM-ICU score in 24-hour period
equals one day of delirium.

Days

Positive/Negative
Every 12 hours

Numeric continuous, ratio

Dependent

Length of stay (SICU)

Number of days of SICU stay

Days

Days (24 hrs)

Ratio

Dependent

Length of stay (Hospital)

Total number of days hospitalized

Days

Days (24 hrs)

Ratio

Dependent

30-day Readmission

A subsequent hospital admission within 30 days
following discharge.

EHR

Incidence of readmission

Dichotomous

Dependent

30-day Mortality

Death (all-cause) occurring 30 days following
hospital admission.

EHR

Incidence of death

Dichotomous

Covariate

Age

The number of years a person has lived.

EHR

Years

Continuous

Covariate

Sex

The physiological state of being male or female.

EHR

Male/Female

Nominal, categorical

Covariate

Admitting Diagnosis

The condition identified by the physician at the
time of admission.

EHR

Type

Nominal, categorical

Covariate
Covariate

Mechanical Ventilation
Richmond Agitation-Sedation
Scale (RASS)

A device that helps patients breathe
A measure of a patient’s level of sedation.

EHR
EHR

Use and duration (hrs)
-5 to +4
Every 4 hours

Dichotomous/ Continuous
Continuous, ratio

Covariate

Propofol Exposure

Propofol administered for sedation

Exposure

Yes/No

Dichotomous

Covariate

Benzodiazepine Exposure

Benzodiazepines administered for sedation

Exposure

Yes/No

Dichotomous
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APPENDIX C
Opioids and Delirium: Table of Evidence
A literature search was conducted with National Library of Medicine Medical Subject
Headings (MeSH) terms opioid AND delirium AND intensive care. Studies published
between 1995 and 2019 were reviewed by using the PubMed database. Inclusion
criteria included: 1) articles written in English; 2) search terms found in the title or as
keywords; 3) study sample defined as adult population; 4) delirium as a primary or
secondary outcome; and 5) intensive care unit setting. Exclusion criteria included: 1)
articles related to the pediatric critical care setting; 2) mixed adult/pediatric studies; 3)
case studies, commentaries, expert consensus, editorials and grey literature; 4) cancer
pain populations and; 5) studies pertaining to general anesthesia management. The
search strategy yielded 78 articles. After title and abstract review, 15 articles met
inclusion criteria and were retained and evaluated for scientific rigor of study design,
methods and analysis. Our literature search, article selection, and evaluation were
guided by PRISMA (Preferred Reporting Items for Systematic Reviews and MetaAnalyses) for quality of reporting for systematic and meta-analyses. Using the Johns
Hopkins Nursing Evidence-Based Practice Research Appraisal Guidelines, the design
and quality of evidence of the articles were assigned an evidence level of I, II, III, IV or V
and graded A (high quality) B (good quality) or C (low quality or major flaws) (see Table
2.1). The Table has been organized as to whether or not the findings supported an
association between opioids and delirium, and the articles are summarized below.
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First
Author,
Year,
Country

Study Aim

Methodology, Study Design

Liu, 2017,
China

To investigate the influence
of opioids and midazolam
sedation on delirium and
outcomes in critically ill
patients and to analyze the
risk factors of delirium.

Single center, prospective randomized
controlled trial

Sample Characteristics

Major Findings/Outcomes

Evidence
Level &
Grade

40% of patients developed
delirium. Significant
differences were noted in
delirium rates among the
three groups (P = 0.014),
22.9% for the remifentanil
group, 40% for the fentanyl
group, and 57.1% for the
control group.

Level I
Grade B

Opioids Reduce Risk of Delirium

Patients were randomly divided into three
groups: 1) remifentanil and midazolam, 2)
fentanyl and midazolam, and 3) the control
group received only midazolam.

Patients admitted to the surgical
intensive care unit who required
sedation and were undergoing
mechanical ventilation for longer
than 24 hours.
Sample Size: 105
Age, mean (SD)

Delirium assessed using the CAM-ICU.
Remifentanil and midazolam (n = 35)
66 yrs (11.94 yrs)
Fentanyl and midazolam (n = 35)
62 yrs (9.96 yrs)
Control Group - Midazolam (n = 35)
64.49 yrs (10.01 yrs)

Agarwal,
2010,
United
States

To evaluate the prevalence
of delirium in ventilated burn
patients and to identify
delirium risk factors.

Retrospective, observational cohort study
Burn patients often experience longer
periods of mechanical ventilation and ICU
care, making this a population at risk for
developing delirium and its associated
complications.
Delirium assessed using the CAM-ICU.

Adult burn patients receiving
mechanical ventilation.
Sample size: 82
Age median (IQR): 48 yrs (38-62 yrs)

Compared to the control
group, remifentanil had a
significantly lower rate of
delirium (P = 0.007).
The logistic regression
analysis
demonstrated that
remifentanil (OR 0.230,
95%Cl 0.074±0.711, P =
0.011) is independent
protective factor for delirium.
The prevalence of delirium
was 77% (63 of 82 patients)
with a median duration of 3
(1-6) days.

Level III
Grade A

Exposure to intravenous
opiates (0.5 [0.4-0.6], P <
.001) and methadone (0.7
[0.5-0.9], P = .02) were
associated with a lower risk
of delirium.
Opiates and methadone
reduced the risk of
developing delirium, possibly
through reduction of pain in
these patients.
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Opioids Not Associated with Delirium
Sieber,
2011,
United
States

To determine the
relationship between opioid
consumption and cognitive
impairment following hip
fracture repair.

Prospective study of consecutive patients.
Pain, opioid consumption, and
postoperative delirium was recorded.

Patients ≥65 years old undergoing
hip fracture repair
Sample Size: 236
Age mean (SD): 81 yrs (7.1 yrs)

Delirium assessed using the CAM.
Delirium (n = 60)
83 yrs (6.9 yrs)

There was no association
between the use of any
postoperative opioid and
incident delirium (P = 0.615)

Level III
Grade A

Opioid dose (P ≥ 0.591) on
postoperative days 1 and 2
was not predictive of incident
delirium.

Non delirium (n=176)
81 yrs (7.1 yrs)
Tedders,
2014,
United
States

To compare the efficacy and
safety of fentanyl versus
traditional sedation with
propofol in critically ill
patients receiving
mechanical ventilation.

Retrospective, observational cohort study

Patients admitted to the ICU

Patients greater than 18 years of age
receiving mechanical ventilation for a
minimum of 24 hours were eligible for
inclusion in this study.

Sample Size: 100
Age years, median (IQR)

No difference in the rate of
intensive care unit delirium
was noted between groups
(fentanyl 23% vs propofol
27%, p=0.80).

Level III
Grade B

Lorazepam was an
independent risk factor for
daily transition to delirium
(OR, 1.2; P 0.003), although
the four medications were
associated with trends toward
significance (midazolam OR,
1.7; P = 0.09; fentanyl OR,
1.2; P = 0.09; morphine OR,
1.1; P = 0.24; propofol OR,
1.2; P = 0.18).

Level III
Grade A

The incidence of delirium
within 5 days was 11.7% (35
of 299) with 8.6% occurring in
the dexmedetomidine group
and 15% occurring in the
morphine group (RR 0.571,
95% CI 0.256-1.099, p =
0.088).

Level I
Grade A

Fentanyl (n=50)
70yr (59yr–83yr)

Delirium assessed using the CAM-ICU.
Propofol (n=50)
63yr (57yr–78yr)
Panharipan
de, 2006,
United
States

To determine whether
sedative and opioid
analgesic medications
independently increased the
probability of daily transition
to delirium.

Cohort study
Markov regression modeling (adjusting for
11 covariates) was used to determine the
probability of daily transition to delirium as
a function of sedative (midazolam,
propofol) and analgesic (fentanyl,
morphine) dose administration during the
previous 24 h.

Mechanically ventilated patient
admitted to the medical or coronary
ICUs
Sample Size: 198
Age, mean (SD): 56 yrs (17.0 yrs)

Delirium assessed using the CAM-ICU.
Shehabi,
2009,
Australia
and New
Zealand

To assess the
characteristics of
dexmedetomidine compared
with morphine-based
regimen after cardiac
surgery at equivalent levels
of sedation and analgesia.

Randomized, double-blind, controlled trial

Cardiac surgery patients > 60 years

Study drug infusions were started in the
ICU. The infusion was continued until the
removal of chest drains, when patient was
ready to discharge from ICU, or for up to 48
hours of mechanical ventilation.

Sample size: 306
Age, Median (IQR)

Delirium assessed using the CAM-ICU.

Morphine (n= 147)
71 yrs (65 – 75 yrs)

Dexmedetomidine (n=152)
71.5 yrs (66 – 76 yrs)
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Opioids Increase Risk of Delirium
Dubois,
2001,
Canada

To establish risk factors for
the development of delirium
in the ICU.

Prospective study.
Delirium was assessed by the intensivist
and confirmed by formal psychiatric
assessment.

Consecutive patients aged 18 or
older admitted to the ICU for > 24
hours.

19% of patients developed
delirium.

Sample Size: 198
Age, mean (SD)

In a multivariate analysis,
morphine, in all dosages, was
significantly linked to the
development of delirium (OR
between 6 and 9.2).

Delirium (n=38)
63 yrs (13.9 yrs)

Level III
Grade A

No Delirium (n = 160)
66 yrs (13.4 yrs)
Marcantoni
o, 1994,
United
States

To examine the role of
medications with known
psychoactive properties in
the development of
postoperative delirium.

Nested case-control study within a
prospective cohort study.

One or two controls were matched to
each case of delirium.

Exposures to opioids, benzodiazepines,
and anticholinergics were recorded for the
24-hour period before delirium developed
in the 91 cases and for the same 24-hour
postoperative period for the 154 matched
controls.

Sample Size: 245
Age, mean (SD)

Delirium assessed using the CAM.
Clegg,
2011,
United
Kingdom

To identify prospective
studies that investigated the
association between
medications and risk of
delirium

Meta-analysis

Pisani,
2009,
United
States

The objective of this study
was to examine the impact
of benzodiazepine or opioid
use on the duration of ICU
delirium in an older medical
population.

Prospective cohort study.

Systematic review of randomized controlled
trials, prospective cohort studies and case–
control studies that reported on
medications and delirium in hospital
patients or long-term care residents.

Delirium (n=91)
73 yrs (8 yrs)
Controls (n=154)
73 yrs (8 yrs)
Fourteen studies were included.
Seven studies included opioid use
across multiple settings (ICU and
Hospital).

Delirium was significantly
associated with postoperative
exposure to meperidine
(odds ratio [OR], 2.7; 95%
confidence interval [CI], 1.3
to 5.5).
Opioids as a class of
medication (OR, 1.4; 95% CI,
0.5 to 4.3) were not
significantly associated with
delirium.
Pooling data from two
studies, delirium risk is
increased with opioid
administration (odds ratio
[OR] 2.5, 95% CI 1.2-5.2).

Consecutive patients age 60 and
older admitted to the medical ICU.

Delirium occurred in 79% of
patients.

Recorded use of opioids (fentanyl and
morphine), benzodiazepines (lorazepam
and midazolam), and propofol on a daily
basis.

Sample Size: 304
Age, mean (SD): 75 yrs (8 yrs)

The median duration of ICU
delirium was 3 days with a
range of 1-33 days.

Delirium assessed using the CAM.

Delirium (n=239)
Benzodiazepine or Opioid Use
(n=247)

Level III
Grade A

Level I
Grade B

Level III
Grade A

Receipt of an opioid (rate
ratio [RR] 1.64, 95%
confidence interval [CI] 1.272.10) was associated with
increased delirium duration.
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Burry,
2017,
Canada

Investigate the relationship
between benzodiazepines,
propofol, opioids and
delirium

Prospective observational study

Critically ill adult patients admitted ≥
24h to 6 different intensive care units

During ICU admission, no patient was
managed with a standardized sedation
protocol (i.e., propofol, benzodiazepine).

Sample Size: 520
Age, mean (SD)

Delirium assessed using the Intensive Care
Delirium Screening Checklist

No Delirium (n = 260)
58 yrs (17.8 yrs)

Delirium was detected in 260
(50%) patients. The median
(IQR) duration of delirium
was 2 (1-5) days.

Level III
Grade A

Patients with delirium
received more opioid
(P=0.0008) drugs than
patients without delirium.

Delirium (n = 260)
62 yrs (16.2 yrs)

Pisani,
2010,
United
States

To identify factors
associated with persistent
delirium in an older medical
intensive care unit (ICU)
population.

Prospective cohort study
Persistent delirium was defined as delirium
occurring in the ICU and continuing upon
discharge to the ward.
Delirium assessed using the CAM.

Consecutive admissions to the
medical ICU patients 60 years or
older
Sample Size: 173
Persistent delirium 58% (n = 100)
Age > 75 (n=49)
Non-persistent delirium 42% (n = 73)
Age > 75 (n=24)

Sosa,
2017,
Argentina

To describe the incidence
of and risk factors for
delirium in the intensive care
unit .

Prospective observational study

Patients admitted to the ICU

The PRE-DELIRIC model assesses 10 risk
factors for delirium that are readily
observable within the first 24 hours
following ICU admission.

Sample Size: 178
Age mean (SD) 64.3 yrs (17.9 yrs)
No Delirium (n=129)
60.9 yrs (18.4 yrs)

Delirium assessed using the CAM.
Delirium (n=49)
74.4 yrs (9.4 yrs)

In a multivariable logistic
regression model, factors
significantly associated with
persistent delirium included
age more than 75 years
(odds ratio [OR], 2.52; 95%
confidence interval [CI], 1.235.16), and opioid (morphine
equivalent) dose greater than
54 mg/d (OR, 2.90; 95% CI,
1.15-7.28).

Level III
Grade A

27.5% of patients developed
delirium.

Level III
Grade A

Predictive factors for the
development of delirium were
increased age, prolonged
ICU stay, and opioid use (OR
4.32; P = .003; CI: 1.64 –
11.38).
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APPENDIX D
Propofol and Delirium: Table of Evidence
A literature search was conducted with National Library of Medicine Medical Subject
Headings (MeSH) terms propofol AND delirium. Studies published between 1995 and
2019 were reviewed by using the PubMed database. Inclusion criteria included: 1)
articles written in English; 2) search terms found in the title or as keywords; 3) study
sample defined as adult population; 4) delirium as a primary or secondary outcome; and
5) intensive care unit setting. Exclusion criteria included: 1) articles related to the
pediatric critical care setting; 2) mixed adult/pediatric studies; 3) case studies,
commentaries, expert consensus, editorials and grey literature; 4) chronic or cancer pain
populations and; 5) studies pertaining to general anesthesia management, not intensive
care unit sedation. The search strategy yielded 51 articles. After abstract review, 15
articles met inclusion criteria and were retained and evaluated for scientific rigor of study
design, methods and analysis. Our literature search, article selection, and evaluation
were guided by PRISMA (Preferred Reporting Items for Systematic Reviews and MetaAnalyses) for quality of reporting for systematic and meta-analyses. Using the Johns
Hopkins Nursing Evidence-Based Practice Research Appraisal Guidelines (see Table
2.1), the design and quality of evidence of the articles were assigned an evidence level
of I, II, III, IV or V and graded A (high quality) B (good quality) or C (low quality or major
flaws). The Table has been organized according to comparators: propofol and delirium,
opioids, benzodiazepines and dexmedetomidine. The articles are summarized below.
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First Author,
Year, Country

Study Aim

Methodology, Study Design

Sample Characteristics

Jiang, 2017,
China

To analyze various risk
factors for
postoperative delirium
after spine surgery in
the middle- and oldaged patients.

Retrospective cohort study

Patients who underwent spinal surgery.

Delirium assessed using cognitive
tests consisting of Clinical Dementia
Rating and Global Deterioration Scale.

Sample Size: 451 patients
Age, mean (SD), years: 65 (18.3) years

To identify the
incidence of delirium,
compare the
demographic and
clinical characteristics
of patients with and
without delirium.

Prospective cohort study

Patients admitted to the Intensive Care
Unit

Major Findings/Outcomes

Evidence
Level &
Grade

A total of 42 (9.3 %) patients
were diagnosed with delirium.

Level III
Grade B

Propofol and Delirium

Mori, 2016,
Brazil

Delirium assessed using the CAMICU.

Sample Size: 149
Age years, median (IQR)
With Delirium (n=69)
65 (22.0 yr)

Bryczkowski,
2014, United
States

This study aimed to
identify modifiable
factors that would
predict delirium in an
older trauma
population admitted to
the SICU.

Prospective cohort study
Delirium assessed using the CAMICU.

Without Delirium (n=80)
54 (24.3 yr)
Consecutive patients older than 50
years, admitted to the SICU.
Sample Size: 115
Age, mean (95% CI)
With Delirium (n=69)
68yr (65yr – 71yr)

Delirious and non-delirious
patients had no difference in
use of propofol.
Of the total 149 patients in the
sample, 69 (46.3%) developed
delirium during ICU stay.

Level III
Grade A

Propofol was utilized in 33% of
patients with delirium compared
to just 7.5% of patients without
delirium (p < 0.001).

The average propofol dose in
patients with delirium was 6
mg/kg/d compared to 1 mg/kg/d
in patients without delirium
(p<0.001).

Level III
Grade C

Significant risk factors
influenced by clinical treatment
included doses propofol.

Without Delirium (n=46)
65yr (62yr – 68yr)

130

Comparison Studies – Opioids
Tedders, 2014,
United States

To compare the
efficacy and safety of
fentanyl versus
traditional sedation
with propofol in
critically ill patients
receiving mechanical
ventilation.

Retrospective, observational cohort
study
Patients greater than 18 years of age
receiving mechanical ventilation for a
minimum of 24 hours were eligible for
inclusion in this study.
Delirium assessed using the CAMICU.

Patients admitted to the ICU
Sample Size: 100
Age years, median (IQR)

No difference in the rate of
intensive care unit delirium was
noted between groups (fentanyl
23% vs propofol 27%, p=0.80).

Level III
Grade B

Higher daytime propofol doses
were marginally associated with
delirium (p = .06), whereas
nighttime change in propofol
dose was not associated with
delirium the following day (p =
.27).

Level III
Grade B

Using a per-protocol analysis,
the incidence of delirium for the
entire study population was
34% (31/90).

Level I
Grade A

Fentanyl (n=50)
70yr (59yr–83yr)
Propofol (n=50)
63yr (57yr–78yr)

Comparison Studies – Benzodiazepines
Seymour,
2012, United
States

To determine whether
benzodiazepine and
propofol doses are
increased at night and
whether daytime and
nighttime sedative
doses are associated
with delirium, coma,
and delayed liberation
from mechanical
ventilation.

Single-center, prospective cohort
study

Adult patients receiving mechanical
ventilation for >12 hrs.

Hourly doses of benzodiazepine and
propofol exposure were measured
during the daytime (7 AM to 11 PM)
and nighttime (11 PM to 7 AM) for 5
days.

Sample Size: 140
Age, median (IQR): 66yr (55yr–75yr)

Investigated the effects
of postoperative
sedation on the
development of
delirium in patients
undergoing cardiacvalve procedures.

Randomized, open-label, controlled
trial

Patients schedule for elective cardiac
valve operations.

After weaning from bypass, patients
were randomly assigned to
postoperative sedation regimens.
Patients were extubated while still on
the medication and were kept on the
maintenance infusion as deemed
clinically necessary for a maximum of
24 hours.

Sample size: 118 randomized, 90
analyzed.
Age, mean (SD)

Delirium assessed using the CAMICU.
Comparison Studies – Dexmedetomidine

Maldonado,
2009, United
States

Delirium assessed by a trained
neuropsychiatrist.

Dexmedetomidine (n= 40)
55yr (16yr)
Propofol (n= 38)
58yr (18yr)

The incidence of delirium was
statistically different between
the three groups (p < 0.001):
Dexmedetomidine = 3% (1/30)
Propofol = 50% (15/30)
Midazolam = 50% (15/30)

Midazolam (n= 40)
60yr (16yr)
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Subramaniam,
2019, United
States

To evaluate the effect
of postoperative
intravenous (IV)
acetaminophen vs
placebo combined with
IV propofol vs
dexmedetomidine on
postoperative delirium
among older patients
undergoing cardiac
surgery.

Randomized, placebo-controlled trial

Patients undergoing cardiac surgery.

Patients were randomized to one of
four groups; postoperative analgesia
with acetaminophen or placebo (0.9%
saline) and postoperative sedation
with dexmedetomidine or propofol.

Sample size: 120 patients
Age; median (IQR)

Delirium assessed using the CAMICU.

Acetaminophen and dexmedetomidine
(n = 29)
64yr (63yr-72yr)

Delirium was reported in 21% of
patients receiving propofol vs
17% of patients receiving
dexmedetomidine.

Level I
Grade A

No significant difference in
delirium between groups was
reported ((difference, -4%) p =
.54).

Placebo and dexmedetomidine (n = 30)
69yr (63yr-74yr)
Acetaminophen and propofol (n = 31)
70yr (66yr-75yr)

Chuich, 2019,
United States

Liu, 2017,
United States

This study evaluates
the effects of the
intraoperative and
postoperative use of
dexmedetomidine
versus propofol
infusions.

To compare the effects
of dexmedetomidine
and propofol sedation
on outcomes in adult
patients after cardiac
surgery.

Retrospective observational study

Placebo and propofol (n = 30)
71yr (64yr-79yr)
Patients undergoing cardiac surgery.

Patients received either
dexmedetomidine or propofol infusion
in addition to general anesthesia
intraoperatively and as a
postoperative sedative.

Sample size: 278 patients
Age; median (range)

Delirium assessed using the CAMICU.

Propofol (n = 209)
67yr (58yr-74yr)

Meta-analysis

Patients undergoing cardiac surgery.

Dexmedetomidine (n = 69)
63yr (56yr-71yr)

Sample size: 969
8 studies met the selection criteria
4 studies (Liu 2016; Corbett 2005;
Djaiani 2016; Maldonado 2009) used
propofol as a comparator with a total
number of 393 accrued participants.

There was no significant
association between use of
dexmedetomidine or propofol
and incidence of delirium (p =
0.27) after adjusting for
covariates.

Level III
Grade A

Pooling of data from 4 studies
showed the incidence of
delirium to be 23.5% in the
propofol group compared to
9.3% in the dexmedetomidine
group (p < 0.001).

Level I
Grade A

Meta-analysis showed that the
dexmedetomidine sedation
significantly decreased
postoperative delirium (POD;
RR, 0.40; 95% CI, 0.24-0.64; P
= .0002).

132

Liu, 2016,
United States

Jiang, 2016,
United States

To compare the effects
of dexmedetomidine
and propofol on
sublingual
microcirculation in
patients after cardiac
surgery.

To assess the
prevalence of delirium
in mechanically
ventilated patients
sedated with
dexmedetomidine or
propofol.

Prospective, randomized, single-blind
study
Patients were assigned randomly to
receive either dexmedetomidine or
propofol upon admission to the ICU.

Patients undergoing cardiac surgery.
Sample Size: 61
Age, median (range)

Incidence of delirium was 6% in
the propofol group, compared to
0% in the dexmedetomidine
group (p = 0.493).

Level I
Grade C

The rates of delirium were
similar in both groups, with 20%
in propofol-treated patients vs.
16% in the dexmedetomidine
group (p = 0.63).

Level III
Grade B

A total of 17.5% and 31.1% of
patients in the
dexmedetomidine and propofol
groups respectively, developed
delirium (p = 0.028).

Level I
Grade A

CAM-ICU scores were reported
in 79% of dexmedetomidine
patients and 84% of propofol
patients (p = 0.411).

Level III
Grade B

Propofol (n = 32)
55yr (48yr-62yr)

Delirium assessed using the CAMICU.

Dexmedetomidine (n = 29)
53yr (48yr-63yr)

Retrospective cohort study

Patients admitted to the medical or
surgical intensive care units.

Patients received either
dexmedetomidine or propofol for 24
hours or more for sedation.

Sample Size: 111
Age, years (range)

Delirium assessed using the CAMICU.

Dexmedetomidine (n= 56)
73yr (50yr–94yr)
Propofol (n = 55)
68yr (22yr–93yr)

Djaiani, 2016,
Canada

Wanat, 2014,
United States

To assess if
dexmedetomidine in
comparison to propofol
sedation after cardiac
surgery would reduce
the incidence of
postoperative delirium.

This study compares
sedation with
dexmedetomidine
versus propofol in
mechanically ventilated
patients after
cardiovascular surgery.

Single-blind, prospective, randomized
controlled trial
Upon arrival to ICU, sedation was
initiated. The infusion was continued
for a maximum period of 24 hours.

Patients undergoing cardiac surgery.
Sample size: 185
Age, mean (SD)
Dexmedetomidine (n= 91)
73yr (6.4yr)

Delirium assessed using the CAMICU.

Propofol (n= 92)
73yr (6.2yr)

Retrospective cohort study

Patients admitted to the ICU after
cardiovascular surgery.

Sedation orders were based on
individual physician ordering upon
arrival to the ICU.

Delirium assessed using the CAMICU.

Sample size: 352
Age, mean (SD)
Dexmedetomidine (n= 33)
63yr (14.1yr)

Incidence of delirium (any vs.
none) was similar between both
groups (9.09% vs. 7.52%, p =
0.747).

Propofol (n= 319)
68yr (11.2yr)
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Xia, 2013,
China

Corbett, 2005,
United States

To assess the
influence of
dexmedetomidine
and propofol sedation
on adverse events for
adults in the intensive
care unit.

Meta-analysis

To assessed patientperceived satisfaction
with coronary artery
bypass graft surgery
after administration of
dexmedetomidine or
propofol for sedation.

Prospective, randomized clinical study

The primary outcomes of this study
were length of ICU stay, duration of
mechanical ventilation, and risk of ICU
mortality. Secondary outcomes
included risk of delirium.

Patients were randomized to either
dexmedetomidine or propofol.
Delirium was assessed by a modified
Hewitt-sedation questionnaire was
administered by the study investigator.

Ten randomized controlled trials,
involving 1202 patients, were included.
Three studies (Maldonado 2009;
Corbett 2005; Jakob 2012) comprised
of 658 patients, reported the incidence
of delirium.
Patients in the surgical ICU following
cardiac surgery.
Sample size: 89
Age mean (SD)

Delirium rates were significantly
lower with dexmedetomidine
compared with those with
propofol (RR, 0.40; 95% CI,
0.22-0.74; p = 0.003).

Level I
Grade A

One episode of delirium
occurred in the
dexmedetomidine treatment
arm and one episode occurred
in the propofol treated patients.

Level I
Grade C

Dexmedetomidine (n = 43)
64yr (10.1yr)
Propofol (n = 46)
63yr (10.7yr)
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